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Colonization is prerequisite for infection and transmission of Streptococcus pneumoniae,
or pneumococcus. Currently available pneumococcal conjugate and pneumococcal
polysaccharide vaccines can provide protection against a limited number of capsular serotypes.
Implementation of vaccines has decreased the frequency of invasive pneumococcal disease and
their colonization rates, but only in a serotype-dependent manner. This has led to serotype
replacement in pneumococcal ecology and increased invasive disease caused by non-vaccine
serotypes. Development of conserved protein-based vaccine that can provide protection against
all pneumococcal serotypes is needed. Numerous surface proteins are conserved in all serotypes,
and some are known to be involved in the colonization process. Understanding how
pneumococcal surface proteins interact with host cells and determining their roles in colonization
will aid in vaccine development. In this dissertation, we characterized host cell receptors of
pneumococcal surface proteins, and proteins involved in biofilm formation, and their effect in
colonization. We utilized a novel protein expression vector, pOS1, which can express secreted
proteins with no LPS, IPTG induction, or cell lysis requirement. These expressed recombinant
proteins were used for further investigation. We identified that human Annexin A2 (ANXA2)

interacts with pneumococcal surface adhesion A (PsaA) protein. ANXA2 transduced cells
showed significant increase in binding with pneumococcus compared to non-transduced cells.
We conducted proteomic profiling of planktonic and biofilm membrane proteins and identified
that two lipoproteins (AmiA, SP_0148) were overexpressed during biofilm formation. Isogenic
mutants lacking these individual proteins showed decreased in biofilm formation compared to
their parental strain. Deletion of SP_0148 led to decreased adhesion of pneumococcus to human
nasopharyngeal epithelial cells (Detroit 562). These results increased our understanding of
pneumococcal surface proteins involved in biofilm-formation and colonization as well as
identifying new host receptors ligands for these adhesins.
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CHAPTER I
INTRODUCTION
1.1

Streptococcus pneumoniae
Streptococcus pneumoniae (pneumococcus) is Gram-positive, alpha hemolytic bacteria

and the leading cause of community acquired pneumonia in the world. Pneumococcus is one of
the leading infectious diseases worldwide and pneumococcus related diseases are the sixth most
common cause of death in the United States (File Jr, 2004). In 2017, the number of invasive
pneumococcal disease (IPD) cases among children aged younger than 5 was seven per 100,000
in the United States and the case of non-invasive disease was higher than IPD. For instance,
otitis media is one of the most common disease among children and the number of cases was
358.7 per 1,000 (Hu et al., 2020). Pneumococcus is commonly found in 20-40% of human
population where they asymptomatically colonize the nasopharynx, however, this bacterium can
cause IPD when it gains access to sterile human body sites such as blood and spinal fluid (Gratz
et al., 2015). This can lead to sepsis and meningitis often resulting in death, especially in young
children or the elderly.
Antibiotics remain the primary treatment option for pneumococcal infection. However,
like numerous other bacterial pathogens, pneumococcus has developed antibiotic resistance over
the last few decades. The first penicillin resistant pneumococcus was identified in 1967 in
Australia and since then a large number of additional penicillin resistant or multidrug resistant
pneumococcal strains were identified worldwide regardless of region or serotypes (Linares et al.,
2010). Thus, antibiotics are rapidly becoming an imperfect solution for treating pneumococcal
1

infection. There are several available vaccines against pneumococcus which provide efficacious
protection against IPD. Despite the approval and implementation of vaccines since the 1980’s,
pneumococcal infection continues to result in severe disease and death, leading to a huge
economic burden ($3.5 billion in U.S) (Huang et al., 2011).
1.2
1.2.1

Current vaccines
Pneumococcal capsule
Some pathogenic bacteria including Escherichia coli, Haemophilus influenzae, Klebsiella

pneumoniae, Staphylococcus aureus, and Streptococcus pneumoniae possess polysaccharide
capsule which contributes to bacterial pathogenicity. While many pathogenic bacteria produce
only a limited number of capsular serotypes, pneumococcus can produce a multitude of diverse
capsular polysaccharides (CPS). A few years ago, researchers stated that there are around 90
different serotypes of pneumococcus. However, recent study identified a new 100th serotype in
2020 and new serotypes continue to be identified (Ganaie et al., 2021; Ganaie et al., 2020). The
CPS is an important contributor to IPD, aiding the bacteria in evading the host immune system
and invasion of sterile human body sites. In general, only about 30 types are responsible for the
majority of IPD cases (Martens et al., 2004). Mechanistically, the capsule can prevent bacterial
uptake by phagocytes and provide protection from killing by host antibodies and complement.
While the capsule can plays an important role during infection, most serotypes can reduce
expression of capsule during colonization and initial biofilm formation (Moscoso et al., 2006).

2

1.2.2

Current pneumococcal vaccines
Currently, two kinds of pneumococcal vaccines are approved in the U.S including

pneumococcal conjugate vaccine (PCV) and pneumococcal polysaccharide vaccine (PPSV). In
general, PPSV includes only polysaccharide of pneumococcus which is capsule and PCVs that
include sugar and some carrier proteins that can enhance the human immune system for better
protection and memory. The PPSV23 was licensed in 1983 but was only effective in adults and
recommended for the elderly or high risk adults with special medical conditions. Another
conjugate vaccine PCV7 was licensed in the U.S in 2000 and later six additional serotypes were
added with PCV13 becoming available in 2010. Now additional PCV15 and PCV20 are
approved in U.S. This conjugate vaccine (PCV13) improved efficacy in young children and is
recommended for children younger than 2 years old (CDC, 2019). Since implementation of the
vaccines, follow up studies identified that the vaccine could decrease the prevalence of penicillin
or multidrug resistant pneumococcus by 57-59% (Kyaw et al., 2006).
A study conducted in England observed prevalence of carriage of PCV13 vaccine
serotypes decreased to less than 6% after vaccine was introduced (Van Hoek et al., 2014). While
the current vaccines reduce invasive pneumococcal disease, these vaccines do not provide
protection against serotypes that are not included in vaccines (Kim et al., 2017). As we use
vaccines, the incidence of pneumococcus in human has quickly changed, resulting in
replacement with non-vaccine serotypes within the population and increases of IPD caused by
these serotypes (Isturiz et al., 2017). Thus, we need to develop new non-serotype-dependent
vaccines, preferably based on conserved proteins, to provide better protection against
pneumococcal disease and colonization.

3

1.3
1.3.1

Interactions with host
Colonization
Streptococcus pneumoniae is an opportunistic pathogen that can colonize the upper

respiratory tract. The rate of colonized children with pneumococcus varies depending on the
region, with prevalence in Africa (48-90%) being significantly greater than in the U.S and
European countries (35-52%) (Abdullahi et al., 2012). There are multiple factors that impact how
pneumococcus colonizes the host epithelium: interactions with epithelial receptors and the
complement system, mucus degradation, metal binding, impairment of neutrophil activity and
pro-inflammatory effects of the pneumolysin toxin. Among these factors, adherence to host
epithelium cells is required as the first step for colonization (Weiser et al., 2018). When
pneumococci adhere to nasopharyngeal epithelial cells, they first encounter the mucus area
which can capture the bacteria, but the negatively charged pneumococcal polysaccharide
capsules can repel the sialic acid-rich mucopolysaccharides in mucus, allowing pneumococcus to
avoid capture and leads to adherence to epithelial cells (Nelson et al., 2007). Streptococcus
pneumoniae utilizes several surface proteins called adhesins to interact with host cells. These
adhesins can bind to host cell receptors that aid pneumococcus in colonization. Adhesins are
usually surface-located proteins such as pneumococcal adherence and virulence protein A
(PavA), PavB and enolase (Eno), these proteins can bind to the extracellular matrix proteins
fibronectin and plasminogen. Another example of interaction between adhesin and host cell is
phosphorylcholine (ChoP) which is located on cell wall teichoic acid, ChoP binds to the plateletactivating factor receptor (PAFR). Thus, choline-binding protein A (CbpA) is known to bind the
secretory component of the polymeric immunoglobulin receptor and host proteins factor H and
vitronectin (Weiser et al., 2018).
4

The family of ATP-binding cassette (ABC) transporters can contribute to adhesion. The
ABC transporters export or import various essential substrates for bacterial growth including
sugar, amino acids, peptides, and antibiotics. There are more than 68 known ABC transporters in
pneumococcus, most of transporters are conserved in all different serotypes. The ABC
transporters are composed of 4 main domains: two transmembrane domains (permeases), two
nucleotide-binding domains (ATPases). Especially, import ABC transporters have an additional
protein called substrate-binding protein (lipoprotein) which binds specific substrate and is
attached to the outer surface of pneumococcus (Durmort & Brown, 2015). Previous studies
indicated that some ABC transporters are capable of transportation as well as adhesion to host
cells. The lipoprotein of polyamine transporter, PotD, is shown to play an important role in
colonization, pneumonia, and meningitis in murine model (Ware et al., 2006). Some
oligopeptide-binding lipoproteins such as AmiA, AliA, and AliB are involved in nasopharyngeal
colonization. The study showed a triple mutant (AmiA, AliA, AliB) led to reduction in
colonization (Kerr et al., 2004). The ABC transporter for manganese is known as PsaA, this
lipoprotein can contribute to host adherence and it can bind to E-cadherin (Anderton et al.,
2007).
1.3.2

Invasion
In most cases pneumococcal colonization is asymptomatic, but if the organism invades

sterile body sites, it can lead to serious IPD such as pneumonia, sepsis, and meningitis.
Pneumococcus utilizes several methods such as receptor-mediated translocation and direct
cellular damage to invade host barriers. In order to invade a sterile body site, pneumococcus
must penetrate or transit across epithelial and endothelial cells. For instance, meningitis is caused
when pneumococcus invades the blood stream and crosses the blood-brain barrier. The precise
5

mechanism by which pneumococci cross the blood-brain barrier invasion is not well known, but
evidence points to several possibilities: destruction of endothelial layer, translocation between
endothelial cells and blood-brain barrier by disruption of cell-cell tight junction, and transcytosis
across endothelial and epithelial cell layer by receptor binding (Iovino et al., 2016). The most
well-known receptor mediated invasion mechanism is the interaction between ChoP and PAFR.
PAFR is the ligand of platelet-activating factor (PAF) which is involved in pathologic processes,
such as allergy, asthma, septic shock, arterial thrombosis, and inflammation (Honda et al., 2002).
ChoP moieties of pneumococcus can be recognized by PAFR on respiratory epithelial cells and
vascular endothelial cells, this process can cause translocation (Cundell et al., 1995). CbpA
protein of pneumococcus can interact with the laminin receptor of the blood-brain barrier
endothelium which is a common receptor for other pathogens. This interaction can allow
pneumococcus to penetrate the blood-brain barrier (Gratz et al., 2015).
Pneumococcal virulence factors can damage the host cells directly allowing for invasion
of host cells. Pneumolysin (PLY) is cholesterol-dependent cytolysin involved in all stages of
pneumococcal diseases such as adhesion, invasion, and transmission. This pore-forming toxin
can directly puncture cells through its interaction with cholesterol, although it has also been
shown to interact with cellular glycolipid receptors at the surface of human red blood cells
(Shewell et al., 2014). PLY lacks an N-terminal secretion signal, so it was thought that PLY is
only released once the bacteria undergo autolysis due to activity of the cell wall amidases known
as autolysins, but a previous study indicated that PLY can be released in early stage of growth
when autolysis is inactive (Benton et al., 1997). Another study identified that PLY from 18
different serotypes could be localized to the cell wall without cell lysis (Price & Camilli, 2009).
Once PLY interacts with its receptor, it can directly damage various host cells including lung
6

endothelial cells, nasal and tracheobronchial epithelial cells by forming pore within the cell
membrane (Nishimoto et al., 2020).
1.3.3

Transmission
Transmission of pneumococcus is known to be mediated by close contact with carriers

especially in young children. Some studies identified that viral infections could enhance
pneumococcal transmission. A study showed that influenza virus infected mice prior to infection
with different invasive pneumococcal strains had differences in mortality and nasal colonization
(McCullers & Rehg, 2002). Thus, transmission between ferrets showed that when they were coinfected with pneumococcus and influenza virus, more ferrets could shed more pneumococcus
compared to other ferrets that were only infected with pneumococcus (McCullers et al., 2010).
Another study showed that complex of H1N1 influenza virus and other common human
nasopharyngeal bacteria including pneumococcus, M. catarrhalis, and H. influenzae could aid
the survival of influenza virus and enhance the transmission of virus (Rowe et al., 2020). The
inflammation by influenza virus can lead to expression of mucin glycoproteins and higher flow
of mucus than normal. Additionally, more pneumococcus can be secreted when a host is coinfected with virus than only pneumococcal infection (Barbier et al., 2012). The shedding of
pneumococcus can be mediated by PLY, PLY-induced inflammation that can clear the bacteria
from the upper respiratory tract and more pneumococcus can be transmitted (Matthias et al.,
2008).

7

1.4

Research significance
Streptococcus pneumoniae is a leading cause of bacterial pneumonia and can cause other

IPD such as meningitis and sepsis in children. Even though vaccines are available, more than
900,000 children die of pneumococcal disease every year worldwide (Alderson, 2016). While
vaccines have proven efficacious against IPD, several studies have identified an increase of IPD
cases caused by serotypes not included in currently approved vaccines. Additionally, antibiotic
resistance in pneumococcus is a rapidly evolving problem. More than ever, the ongoing COVID19 pandemic has shown us that effective vaccine strategies could save millions of lives and
prevent spread of infection. Therefore, we need to develop a universal pneumococcal vaccine
that is not serotype-dependent. In this study we have attempted to identify which host cell
receptors can interact with pneumococcal adhesins which is a critically important study for
pneumococcal vaccine development. Additionally, we identified which pneumococcal surface
proteins are involved in biofilm formation during early colonization. Thus, this study will aid our
understanding of interactions between host cell receptors and pneumococcal surface proteins
involved in the early prerequisite steps of pneumococcal colonization and disease.
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CHAPTER II
CONSTRUCTION OF NOVEL STAPHYLOCOCCAL PROTEIN EXPRESSION VECTOR
2.1

Abstract
Recombinant proteins have been used in various research areas for decades. E. coli

protein expression systems are used a majority of the time because of their advantages including
speed of growth, abundance of vectors, and wide range of affinity tags and fusions. However,
there are limitations of E. coli recombinant proteins, especially LPS contamination for proteins
to be injected into animals or humans as vaccines study and isopropyl β-D-1thiogalactopyranoside (IPTG) toxicity to protein expression host cells. To circumvent some of
these limitations, we developed a Staphylococcus aureus vector system for recombinant protein
expression and secretion. Our novel expression vector, pOS1, secretes overexpressed
recombinant proteins directly into the bacterial culture medium without any supplements or
inducers. Additionally, the gram-positive system results in no LPS contamination and less
protein contamination from expression strain since cellular lysis is not required. This new tool
will be useful for therapeutic and Gram-positive pathogen study.
2.2

Introduction
Proteins are the key player in living organisms and recombinant proteins have been used

in biological and biomedical science area (Gräslund et al., 2008). Historically, Escherichia coli
(E. coli) systems have been widely for recombinant proteins production and purification. E. coli
is one of the most effective organisms to produce heterologous proteins because of its following
9

characteristics: it is likely the best characterized microorganism, it can be grown rapidly and
cheaply, and there are a wide array of cloning vectors and protein expression host strains
(Baneyx, 1999). E. coli protein expression is undoubtedly an effective system to produce
proteins of interest but there are several drawbacks of E. coli protein expression system such as
formation of inclusion bodies, proteolytic degradation, and disulfide bond formation (Baneyx &
Mujacic, 2004). Additionally, recombinant proteins expressed in E. coli are contaminated with
lipopolysaccharide (LPS; endotoxin) that can induce a pyrogenic response if administered by
vaccination. The elimination of LPS from E. coli-expressed recombinant proteins is the critical
in the human therapeutic industry for uses including vaccination (Jana & Deb, 2005). Our novel
pOS1, shuttle vector, can express proteins of interest in Staphylococcus aureus (S. aureus) and
possesses a signal peptide sequence and 6x histidine-tag (His-tag) resulting in protein secretion
and ease of purification using nickel affinity chromatography. This gram-positive secretory
protein expression system has no LPS contamination and IPTG toxicity complications. Since
recombinant proteins are secreted into bacterial culture medium there is little protein
contamination from the expression host. This system requires no supplements or inducers in the
bacterial culture or any additional process or reagent to lyse the bacteria.
2.3
2.3.1

Materials and Methods
Streptococcus pneumoniae chromosomal DNA isolation
Streptococcus pneumoniae TIGR4 strain was grown on tryptic soy agar supplemented

with 5% of sheep blood for overnight at 37℃ in 5% CO2. The bacteria were grown in 20ml of
C+Y media to mid-logarithmic phase (O.D.600nm 0.6) in a 37℃ water bath (Orihuela et al.,
2004). The bacterial cells were collected by centrifugation at 6000 rpm for 10min and suspended
in 500µl of TES buffer containing 10mM Tris-HCl (pH 7.6), 1mM EDTA, and 0.5 w/v SDS. The
10

suspension was centrifuged at 6000 rpm for 1 min and resuspended in 500µl of TES buffer. The
suspension was treated with following steps: addition of 50µl of 1% Triton X-100 and incubated
at 37℃ for 15min, addition of 50µl of RNase (10mg/ml) and incubated at 37℃ for 15min,
addition of 20µl of Proteinase K and incubated at 37℃ for at least 2 hours. An equal amount of
phenol-chloroform-isoamyl alcohol (25:24:1) was added and vortexed vigorously. The
suspension was centrifuged at 13,000 rpm for 10 min. The top layer was transferred to a new
tube and equal volume of chloroform was added. The suspension was vortexed vigorously and
centrifuged at 13,000 rpm for 10 min. The top layer was collected, and 2 volume of 100%
ethanol was added. The ethanol suspension was centrifuged at 13,000 rpm for 10 min and
supernatant was discarded. The pellet was washed with 70% of ethanol and centrifuged at 13,000
rpm for 15 min. The supernatant was discarded, and excess ethanol was air dried. The air-dried
pellet was resuspended in 50µl of TE buffer (10mM Tris-base, 1mM EDTA, pH 8.0).
2.3.2

Bioinformatic study
Bioinformatics method was conducted to express the candidate for protein-based vaccine

of pneumococcal membrane proteins. Mostly, lipoproteins of ABC transporters that are involved
in colonization or significantly important in lung infection were selected based on transposon
sequencing (Tn-seq) data. Initially, open reading frame (ORF) sequence for each protein of
interest of S. pneumoniae TIGR4 strain was screened from NCBI. Additionally, identification of
protein structure, domain site of protein and potential ligands was determined by I-Tasser
(https://zhanglab.ccmb.med.umich.edu/I-TASSER/) and P-fam (https://pfam.xfam.org/).
TMHMM 2.0 and SignalP 4.1 were used to search the type-I signal peptide and membrane
domains respectively (Olaya-Abril et al., 2013).
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2.3.3

Construction of cloning vector
The 6x histidine tag sequence was designed as sense and antisense PCR primers and

annealed by following gradient PCR condition: 75℃ to 52.5℃ for 1min respectively. The
annealed 6x histidine tag was digested with PstI and BmtI at 37℃ for overnight respectively.
Same enzyme digested pOS1 original vector was digested with PstI and BmtI followed by
ligation to enzyme-digested 6x histidine tag at 16℃ overnight. The 10µl of overnight ligation
was transformed into DH5α E. coli chemically competent cell by heat shock method (Froger &
Hall, 2007). Each three different signal peptides were amplified by PCR from S. aureus. Both the
enterotoxin signal peptide (SEC) and beta-hemolysin signal peptide (Hlb) were amplified from
chromosomal DNA of the methicillin-resistant S. aureus (MRSA) strain MW2 (Baba et al.,
2002). Thus, the last signal peptide of exfoliative toxin (ETA) was amplified from chromosomal
DNA of S. aureus strain UT0003. Each of the 3 signal peptide amplicons and 6x histidine tag
ligated pOS1 vector were digested with EcoRI and BamHI at 37℃ for overnight respectively.
The digested signal peptide amplicons and vector were ligated with T4 DNA ligase (New
England Biolabs, M0202S) at 16℃ overnight. On next day, 10µl of overnight ligation product
was transformed into DH5α E. coli chemically competent cell by heat shock method and plated
on LB (Ampicillin, AMP: 100µg/ml) plate for overnight. Several colonies were chosen for
colony PCR to confirm the transformation and were stored at -80℃ for later use.
2.3.4

Cloning and transformation
Based on the bioinformatic analysis and restriction enzyme availability for cloning, both

forward and reverse primers were designed containing restriction enzyme sites (Figure 2.1). The
gene of interest was amplified with Ex-taq DNA polymerase (Takara, Cat. RR001A) following
manufacturer’s instructions from S. pneumoniae TIGR4 chromosomal DNA. The PCR product
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was cleaned up in 50µl of nuclease free water with commercial kit (Zymo research, Cat. D4033).
PCR products were sequentially digested at 37℃ for overnight. Digested PCR products and
vectors were ligated at room temperature for 2 hours with T4 DNA ligase (New England
Biolabs, M0202S) and 10µl of ligation product was transformed into E. coli chemically
competent DH5α cell (Froger & Hall, 2007). The transformants were grown on LB agar
(AMP:100µg/ml) overnight. A single colony was picked for colony PCR and amplified with
sequencing primers to confirm the gene insertion (Table 1). Positive E. coli transformants were
grown in 5ml of LB (AMP:100µg/ml) media overnight. The plasmid was extracted from E. coli
and 2µl of plasmid was transformed into S. aureus electrocompetent strain RN4220 by
electroporation as previously described (Kraemer & Iandolo, 1990). S. aureus transformants
were grown on brain heart infusion (BHI) agar supplemented with 10µg/ml of chloramphenicol
at 37℃ overnight. A single S. aureus transformant colony was lysed with lysostaphin mixture
(50µl of nuclease free water and 2µl of 1µg/µl lysostaphin) for 1 hour. The lysed mixture was
centrifuged at 13,000rpm for 1min and 1µl of supernatant was amplified with sequencing
primers to confirm the gene insertion (Table 1). The PCR positive S. aureus transformant was
grown in BHI media (CM: 10µg/ml) overnight, supplemented with 20% v/v glycerol and stored
at -80℃ for later use.
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Figure 2.1

Cloning site of pOS1 protein expression vector

Availability of restriction enzyme site of pOS1 vector and all enzymes can let PCR insert in
frame for proper transcription and translation without adding or deleting additional nucleotides to
PCR insert.
2.3.5

Expression of pneumococcal protein and purification
According to the bioinformatics study, a representative pneumococcal surface protein

(SP_1003: phtD) was cloned into 6x histidine pOS1 vector. The pOS1+gene of interest S. aureus
transformant was grown in 1ml of YCP media (yeast extract, casamino acids, pyruvate, salts)
supplemented with 10µg/ml of chloramphenicol at 37℃ overnight (Harper et al., 2018). The
overnight culture was diluted 1:500 into fresh 50ml of YCP media (CM: 10µg/ml) and grown
again overnight. The supernatant of 50ml overnight culture was harvested by centrifugation at
13,000 rpm for 10mins at 4℃. The collected supernatant was filtered through a 0.3µM syringe to
remove excess bacteria and debris. TCA precipitation was conducted to confirm protein
expression by adding 100µl of TCA solution into 900µl of filtered supernatant. TCA suspension
was stored at 4℃ for overnight. Precipitated proteins were harvested by centrifugation at 13,000
rpm for 15 min, the supernatant was discarded, and the pellet was washed with 1ml of ice-cold
100% acetone. Following centrifugation at 13,000 rpm for 15 min, the excess acetone was
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removed by air dry. Precipitated proteins were resuspended in 50µl nuclease free water. 50µl of
2x Laemmli sample buffer (BioRad, 161-0737) supplemented with 5% v/v 2-mercaptoehanol
and pH was adjusted with 1M NaOH. The suspension was heated at 95℃ for 5 min and
centrifuged at 13,000 rpm for 1 min before running on SDS-PAGE to confirm the protein
expression.
Once the protein expression was confirmed, filtered supernatant was conditioned to 1x
binding buffer by adding 7ml of 8x binding buffer into 50ml of filtered supernatant. The protein
was purified by nickel column chromatography method (Fig. 2.2). The optional wash step with
1x wash buffer was conducted if the contaminated proteins were detected in 1x elution buffer
flow through.
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Figure 2.2

Flowchart for cloning and protein purification

Flow through was collected from second 24ml of 1x binding buffer, wash buffer, and elution
buffer to confirm on SDS-PAGE gel where the recombinant proteins are involved. The 12ml of
elution buffer flow through was collected in two separate tubes for better protein concentration:
first 5ml of elution and 7ml of elution. *Optional step.
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2.3.6

Optimal medium for protein expression
We have utilized 2 different media to express proteins in S. aureus. Both BHI and YCP

medium were used to grow S. aureus transformants and 50ml overnight culture was serial diluted
to quantitate the number of bacteria. Both supernatants from 2 different media were precipitated
with TCA to identify the media resulting in optimum protein expression.
2.4
2.4.1

Results
Protein expression from pOS1 vector
A pneumococcal surface protein, Pneumococcal histidine triad protein D (PhtD), which is

a promising vaccine candidate, was expressed in pOS1 vector for further investigation. The
truncated phtD gene was ligated with pOS1 vector and transformed into S. aureus protein
expression strain RN4220. Successful gene insertion was confirmed by PCR amplification with
sequencing primer set (Table A.1). The final transformant was grown overnight and filtered
supernatant was used for TCA precipitation to confirm the protein expression along with vector
only control (Figure 2.3). Once the protein expression was confirmed, 50ml of filtered
supernatant was run through nickel chromatography affinity column to purify the histidine
tagged protein of interest. The purified protein from 1st 5ml of elution was run on SDS-PAGE
gel and stained with Coomassie blue to visualize the protein purity (Figure 2.3).
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Figure 2.3

Expression of SP_1003 (PhtD) recombinant protein from S. aureus transformant

Protein expression was visualized on SDS-PAGE gel followed by Coomassie blue staining. (A)
TCA precipitated supernatant was separated on gel, vector only control (lane 1), gene inserted
vector (lane 2). (B) Purified PhtD protein from nickel chromatography (1st elution).

2.4.2

Protein expression from different media
The proper medium for protein expression and purification was determined in this

protocol. As shown in a previous study, pyruvate in YCP medium causes alterations in the
metabolic pathway of S. aureus and this can lead to the over-production of virulence factors in S.
aureus (Harper et al., 2018). Thus, this medium was tested for this study for effective
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overexpression of PhtD. Two 50ml cultures of the PhtD-positive S. aureus transformant was
made in BHI medium and YCP medium. After overnight incubation, serial dilution was
conducted, and S. aureus colonies were quantitated by colony count. The result of colony count
was 2.05x109 CFU/ml from BHI medium overnight culture and 3.4x109 CFU/ml from YCP
medium culture. Each filtered supernatant was run over the nickel chromatography affinity
column to purify the protein of interest and purified proteins were separated on SDS-PAGE gel.
As shown in figure 2.4, we identified that protein that was expressed from YCP medium was
relatively higher than BHI medium.
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Figure 2.4

Expression of protein of interest (PhtD) from 2 different culture media

Elution from nickel chromatography affinity column was separated on SDS-PAGE gel and
stained with Coomassie blue. Expressed protein from YCP medium culture (lane 1), expressed
protein from BHI medium culture (lane 2).
2.5

Discussion
E. coli protein expression systems have been used for decades to produce recombinant

proteins in various research areas. Undoubtedly, the E. coli system is one of the most useful and
effective methods for protein production. However, there are several limitations in this method
such as inclusion bodies, IPTG toxicity, and LPS contamination. Recombinant proteins produced
by E. coli require LPS detoxification prior to use in in vivo studies to minimize endotoxininduced inflammatory responses and mortality (Vreugdenhil et al., 2003). Additionally, most E.

20

coli protein expression methods require lysis of protein expression host cells, causing
cytoplasmic protein and difficult to purifying a single protein of interest. Current T7 promoterbased E. coli protein expression systems cause metabolic burden from overexpression of proteins
by IPTG induction, this burden makes E. coli host cells overconsume unnecessary metabolic
precursors including amino acids, rRNAs, and ATP to produce foreign proteins along with
maintaining the expression plasmid (Dvorak et al., 2015). Insertion of plasmid, metabolic
burden, and IPTG toxicity can affect E. coli viability and can prevent maintenance of the plasmid
under these harsh conditions (Kurumbang et al., 2014). Often, when high levels of recombinant
proteins are expressed in E. coli, they can form insoluble protein aggregates called inclusion
bodies. Thus, several previous studies indicated how to purify proteins from inclusion bodies
including low-speed centrifugation to sort inclusion bodies from cell wall. To enhance solubility
of inclusion bodies, researchers fuse inclusion bodies with soluble proteins such as maltosebinding protein (MBP), thioredoxin (TRX), transcription pausing factor L (NusA), thiol-disulfide
oxidoreductase, and glutathione S-transferase (GST) (Lavallie et al., 1993; Palmer & Wingfield,
2012; Thapa et al., 2008). However, these insoluble inclusion bodies still require additional steps
to purify protein of interest from the whole E. coli lysates resulting in increased time and costs.
The novel pOS1 vector, reported here, allows for recombinant protein to be secreted into
bacterial culture medium which has the advantages of no LPS contamination, no need IPTG
induction, and no cell lysis and resulting in less proteins contamination from host cell proteins.
Since expression strains of E. coli do not naturally secrete proteins, most of current standard E.
coli systems produce recombinant proteins within their cytoplasm. If the recombinant proteins
could be secreted or located in periplasmic area there are several benefits. Secreted proteins are
not required cell lysis step and if proteins are located in periplasm, simple osmotic shock or cell
21

wall permeabilization method can extract the proteins without cytoplasmic proteins
contamination from host cells (Mergulhão et al., 2005). Proper protein folding and disulfide
bonds formation are critical when recombinant proteins are produced in foreign systems and the
cytoplasmic environment is often not appropriate for proper protein folding. On the other hand,
the periplasm environment has enzymes for disulfide-bonding proteins (DsbA, DsbB, DsbC, and
DsbD) and petidyl-prolyl isomerases (SurA, RotA, FklB, and FkpA) that promote the
appropriate proteins folding (Shokri et al., 2003). Thus, secreted proteins can result in more
products more similar to the original proteins compared to other recombinant proteins made from
standard E. coli methods because of N-terminal of secreted proteins is cleaved and unnecessary
methionine could be removed which is not in original proteins (Mergulaho et al., 2000).
While E. coli protein expression systems are one of the most effective methods in cost
and time, they contain considerable drawbacks. For use in therapeutic applications such as
vaccines, concerns include LPS contamination, IPTG toxicity and codon usage. Our pOS1 vector
can secrete recombinant proteins in culture medium so the proteins can be collected from
supernatant easily and does not require IPTG induction. Thus, secreted proteins of interest are
usually more stable and closer to their original form. This new vector system is more competitive
than standard E. coli system in terms of cost and time, especially for therapeutic purpose
research or Gram-positive pathogen studies.
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CHAPTER III
PNEUMOCOCCAL SURFACE ADHESION A PROTEIN (PSAA) INTERACTS WITH
HUMAN ANNEXIN A2 ON AIRWAY EPITHELIAL CELLS
3.1

Abstract
Streptococcus pneumoniae (pneumococcus) is a normal colonizer of the human

nasopharynx capable of causing serious invasive disease. Since colonization of the nasopharynx
is prerequisite for progression to invasive disease, the development of future protein-based
vaccines requires an understanding of the intimate interaction of bacterial adhesins with host
receptors. In this study, we identified that pneumococcal surface adhesin A (PsaA), a highly
conserved pneumococcal protein known to play an important role in colonization by
pneumococcus, can interact with Annexin A2 (ANXA2) on Detroit562 nasopharyngeal epithelial
cells. Lentiviral expression of ANXA2 in HEK 293 T/17 cells, which normally express minimal
ANXA2, significantly increased pneumococcal adhesion. Blocking of ANXA2 with recombinant
PsaA negatively impacted pneumococcal adherence to ANXA2-transduced HEK cells. These
results suggest that ANXA2 is an important host cellular receptor for pneumococcal
colonization.
3.2

Introduction
Streptococcus pneumoniae (pneumococcus) is a gram-positive bacterium that commonly

colonizes the nasopharynx of humans and is capable of causing invasive pneumococcal disease
(IPD), including pneumonia, bacteremia, and meningitis (Yahiaoui et al., 2016). The currently
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available vaccines in the U.S. are the 13-valent pneumococcal conjugate vaccine (PCV13) and
the pneumococcal polysaccharide vaccine (PPSV23) (Tomczyk et al., 2014). These vaccines
have proven efficacy against most IPD-causing vaccine serotypes (Bonten et al., 2015).
However, these vaccines are less effective at preventing colonization and infection by nonvaccine serotype pneumococcal strains, consequently diseases caused by these non-vaccine
strains are increasing (Moffitt et al., 2011). Since introduction of the current vaccines,
colonization of non-vaccine serotypes has increased with many of these strains being highly
resistant to more than 2 different classes of antibiotics (Huang et al., 2005; McEllistrem et al.,
2005; Obolski et al., 2018). Furthermore, pneumococci are one of numerous naturally competent
bacteria capable of taking up free DNA from pneumococci and other bacteria in vivo (Griffith,
1928; Salvadori et al., 2019). This has resulted in serotype replacement in the face of vaccine
pressure (Steinmoen et al., 2002; Weinberger et al., 2011). Therefore, development of proteinbased vaccines targeting protein antigens that are commonly expressed by pneumococci may
resolve current issues of serotype-dependent vaccines.
The human nasopharynx is the major colonization site for pneumococcus and
colonization is prerequisite for invasive disease (Bogaert et al., 2004). During colonization,
pneumococci expresses various surface proteins and enzymes that interact with host epithelial
cells and facilitate attachment to the upper respiratory tract of humans (Weiser et al., 2018).
Thus, pneumococcal surface proteins and enzymes are ideal vaccine targets to interfere with the
first step of pneumococcal pathogenesis (Bergmann & Hammerschmidt, 2006). So far, the role
of more than 30 pneumococcal surface proteins has been characterized in colonization and
subsequent infectious processes (Weiser et al., 2018). Pneumococcal surface protein adhesin A
(PsaA) is a lipoprotein component of an ABC transporter for manganese (Mn) which has been
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shown to contribute to colonization in humans (Dintilhac et al., 1997). Previous studies
demonstrated that a PsaA-negative mutant displayed lower adherence to human nasopharyngeal
epithelial cells (Detroit 562) and human lung alveolar epithelial cells (A549) compared to
parental strains (Berry & Paton, 1996; Romero-Steiner et al., 2003). Since attachment of
pneumococcus to the epithelium is essential for development of pneumococcal disease,
identifying host cellular receptors of PsaA and other adhesins is critical for development of
vaccines effective at preventing colonization.
Furthermore, PsaA is highly conserved in most pneumococcal serotypes and is
immunogenic in all age groups which make it a potential vaccine candidate (Sampson et al.,
1997). A previous study identified E-cadherin as a potential receptor for PsaA on human
nasopharyngeal cells (Anderton et al., 2007). We hypothesized that PsaA could interact with
additional epithelial receptors and here describe the interaction of PsaA with human Annexin A2
(ANXA2).
3.3
3.3.1

Materials and Methods
Streptococcus pneumoniae chromosomal DNA isolation
Streptococcus pneumoniae strain TIGR4 was grown on tryptic soy agar supplemented

with 5% of sheep blood for overnight at 37℃ in 5% CO2 then inoculated into 20ml of C+Y
media and grown to mid-logarithmic phase (O.D.600nm of 0.6) in a 37℃ water bath (Orihuela et
al., 2004). The cells were collected by centrifugation at 6000 rpm for 10min and suspended in
500µl of TES buffer containing 10mM Tris-HCl (pH 7.6), 1mM EDTA, and 0.5% w/v SDS. The
suspension was centrifuged at 6000 rpm for 1 min and resuspended in 500µl of TES buffer prior
to the following steps: addition of 50µl of 1% Triton X-100 and incubation at 37℃ for 15min,
addition of 50µl RNase (10mg/ml) and incubation at 37℃ for 15min, addition of 20µl Proteinase
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K and incubation at 37℃ for at least 2 hr. An equal amount of phenol-chloroform-isoamyl
alcohol (25:24:1) was added and vortexed vigorously. The suspension was centrifuged at 13,000
rpm for 10 min. The aqueous layer was transferred to new tube and equal volume of chloroform
was added. The suspension was vortexed vigorously and centrifuged at 13,000 rpm for 10 min.
Again, the aqueous layer was collected and 2 volumes of 100% ethanol was added. The ethanol
suspension was centrifuged at 13,000 rpm for 10 min and supernatant was discarded. The pellet
was washed with 70% of ethanol and centrifuged at 13,000 rpm for 15 min. The supernatant was
discarded, and excess ethanol was air dried. The air-dried pellet was resuspended in 50µl of TE
buffer (10mM Tris-base, 1mM EDTA, pH 8.0).
3.3.2

Gene cloning and expression of recombinant PsaA
The psaA gene was amplified from TIGR4 DNA using Ex-taq DNA polymerase (Takara,

Cat. RR001A) following manufacturer’s instructions. Both pOS1 customized vector for protein
expression and purified PCR product were digested with BamHI and XhoI restriction enzymes
(New England Biolabs). Following restriction enzyme digestion, the psaA gene was ligated with
pOS1 customized staphylococcal expression vector that can secrete the protein into the bacterial
culture media. The ligation product was transformed into chemically competent E. coli DH5α
cells (Froger & Hall, 2007). The purified plasmid was extracted from E. coli and electroporated
into S. aureus strain RN4220 as previously described (Kraemer & Iandolo, 1990). A positive S.
aureus transformant was confirmed by PCR and grown overnight in 1ml of YCP media (yeast
extract, casamino acids, pyruvate, salts) supplemented with 10µg/ml of chloramphenicol at 37℃
(Harper et al., 2018). Following incubation, 100µl of culture was transferred to 50ml of fresh
YCP media supplemented with 10µg/ml of chloramphenicol and incubated at 37℃ overnight
and sterile filtered the following day. The filtered culture supernatant was added to nickel resin
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to purify the 6x histidine tagged PsaA by nickel chromatography. The protein purification was
confirmed by SDS-PAGE (Figure B.1).
3.3.3

Biotin labeling of PsaA
The purified PsaA protein was biotinylated using EZ-Link™ NHS-LC-Biotin

(ThermoFisher Scientific #21327) according to the manufacturer’s instruction. The excess nonreacted biotin reagent was removed by PD-10 desalting column (GE Healthcare #17085101) and
biotinylation was confirmed by western blot using HRP conjugated streptavidin.
3.3.4

Extraction of nasopharynx epithelial cell lysate proteins and two-dimensional
electrophoresis
Detroit 562 human nasopharyngeal epithelial cells were grown in EMEM medium

(ATCC, 30-2003) containing 10% fetal bovine serum, 2 mM L-glutamine and
penicillin/streptomycin in T-75 culture flasks, collected by scraping, washed with PBS and
transferred to microcentrifuge tubes. The cell pellets were resuspended in 400µl of TE buffer
(10mM Tris, 1mM EDTA, pH 8.0) and 650µl of Phenol:Chloroform:Isoamyl alcohol (25:24:1)
and vortexed vigorously. The suspension was centrifuged at 13,000 rpm for 15 min and both
aqueous and organic phases were discarded. The interphase was suspended in 1ml of chloroform,
vortexed vigorously, and centrifuged at 13,000 rpm for 5 min. The chloroform layer was
removed and the pellet was air dried. The pellet was resuspended in rehydration buffer (7M urea,
2M thiourea, 0.5% triton X-100, 2mM TBP). A total amount of protein in the samples was
quantified using 2D Quant kit (GE Healthcare) and 100 µg of proteins were separated by 12.5%
SDS-PAGE or 2 DE using 3-11 non-linear pH gradient 7 cm IPG strip (GE Healthcare, #GE176003-73). Isoelectric focusing was performed using a Multiphor II electrophoresis system (GE
Healthcare) in three running phases (phase I, 200V/0.01h; phase II, 3500V/1.5h; phase II,
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3500V/1.05h). The strip was equilibrated in 1% dithiothreitol, followed by 5% iodoacetamide for
10 min in each. The second dimension SDS-PAGE was performed using 12.5% polyacrylamide
gels in duplicate. One gel was stained with colloidal Coomassie (Pierce) and the other gel was
transferred to a PVDF membrane for far western blot analysis.
3.3.5

Far-western blot and mass spectrometry
The PVDF membrane was incubated in AC buffer (100 mM NaCl, 20 mM Tris pH7.6,

0.5 mM EDTA, 10% glycerol, 0.1% Tween 20, 2% skim milk) with a step-wise reduction of the
guanidine-HCl concentration from 6 M, 3M, 1 M, 0.1M, and 0. The PVDF membrane was
incubated with 100 µg of biotinylated PsaA in PBST buffer (4 mM KH2PO4, 16mM Na2HPO4,
115 mM NaCl, pH 7.4) containing 2% skim milk for overnight at 4 oC. After washing with PBST
buffer, PVDF membranes were incubated with a streptavidin bead conjugated with horseradish
peroxidase (HRP) in PBST buffer with 2% skim milk. Binding of biotinylated PsaA to target
protein was detected by enhanced chemiluminescence (ECL) reagent (ThermoFisher Scientific)
and visualized by x-ray film exposure.
To identify epithelial proteins specifically interacting with PsaA, the protein spots in the
Coomassie stained gel were aligned to the PVDF membrane. Corresponding spots form
Coomassie stained gel were excised and digested with trypsin (Worthington). Peptide mass
spectra were generated using MALDI-TOF/TOF (ABI4700) and protein identification was
performed using ABI GPS Explorer software V3.5. Deduced peptide sequence was analyzed
using the Mascot search engine using the SWISS-PROT database. This work was done in our
Center of Biomedical Research Excellence “Omics” Core, which is a component of the Institute
for Genomics, Biotechnology, and Biocomputing.
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3.3.6

ANXA2 recombinant protein
The full codon sequence of ANXA2 isoform 2 gene (NM_001002858.3) was ligated with

pET 21b vector (Novagen, #69741) following the manufacturer’s instructions. The ligation
product was transformed into chemically competent E. coli DH5α cells and subsequently, into E.
coli protein expression strain BL21 (DE3) (Novagen, #69450). The transformant was induced
with 1mM of IPTG at 37°C for overnight. The IPTG induced bacterial cells were lysed with BPER (ThermoFisher Scientific #78243) following manufacturer’s instructions and soluble
proteins were separated from the insoluble proteins by centrifugation at 10,000 x g for 10 min.
The soluble proteins were added to nickel resin to purify the 6x histidine tagged ANXA2 by
nickel chromatography and purified ANXA2 was confirmed by western blot. The purity of the
protein is demonstrated in Figure B.1.
3.3.7

Mouse tissue lysates western blot
Murine tissues of a C57BL/6 mouse were excised from nasopharynx, bronchi, lungs, and

heart. Tissues were homogenized by bead beating and lysed with modified hunter’s buffer
(10mM HEPES, 150mM NaCl, 1.5mM MgCl2, 1mM EDTA, 10mM Na-pyrophosphate, 10mM
NaF, 0.1mM Na3VO4, 1% deoxycholic acid, 1% Triton X 100, 0.1% SDS). Following
centrifugation to pellet debris, protein from lysates were quantitated by BCA assay
(ThermoFisher Scientific #23227) and 25μg from each tissue was subjected to SDS-PAGE on
12% polyacrylamide gel and transferred to PVDF membrane. The expression of ANXA2 was
determined by western blotting probed with ANXA2 antibody (Santa cruz #SC-28385) followed
by goat anti-mouse IgG HRP- conjugated secondary antibody (Bio-Rad #172-1011).
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3.3.8

ANXA2 immunohistochemical (IHC) staining
Murine tissues were excised along the respiratory tract (nasopharynx, bronchi, lungs) and

heart. Tissues were fixed in fixed in formalin, embedded in paraffin, sectioned at 5μm. The
unstained slides were deparaffinized and pretreated with DIVA Decloaker (Biocare) in a
Decloaking Chamber (Biocare) for 15 min at 110°C. Endogenous peroxidase activity was
blocked with 3% hydrogen peroxide for 5 minutes. The 1:100 diluted ANXA2 primary antibody
(Santa Cruz, sc-9061) was applied to the slides for 30 min. A negative control without primary
antibody was included. Detection was performed using Rabbit-on-Canine HRP polymer
(Biocare) according to insert directions. The tissues were developed with DAB chromogen
substrate (Biocare) for 5 min. The slides were counterstained with hematoxylin (Biocare) for 5
min. The slides were washed, dehydrated and coverslipped.
3.3.9

Lentiviral expression of ANXA2
HEK293T cells were obtained from ATCC and cultured in DMEM medium (ATCC, 30-

2002) containing 10% fetal bovine serum, 2 mM L-glutamine and penicillin/streptomycin
(ThermoFisher Scientific). The lentiviral expression plasmid pLenti-C-Myc-DDK harboring the
human annexin A2 (NM_001002858, pLenti-ANXA2) was obtained from Origene (RC215009).
To generate lentiviruses, HEK293T/17 cells were transfected with pLenti-ANXA2 in
combinations with the packaging plasmid, psPAX2 (Addgene) and the envelop plasmid pMD2.G
(Addgene) using TransIT_293 transfection reagent (Mirus). After 24, 48, 72, 96 hours
incubation, the culture supernatant containing lentiviruses was harvested and filtered through a
0.45-μm filter. Fresh HEK 293 T/17 cells were transduced with lentivirus for 12 hr and then
cultured in a 48-well plate for overnight. The following day, cells were transferred to 12-well
plates and cultured for overnight. On day 3, cells expressing ANXA2 were selected by culturing
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DMEM media containing 5µg/ml of puromycin. As a control, HEK 293 T/17 mock cells were
made using empty transfer plasmid following same method as above. To confirm the expression
of ANXA2, 4 different cell lines (Detroit 562, A549, HEK 293 T/17 Mock, and ANXA2
transduced HEK 293 T/17) were lysed with RIPA buffer (ThermoFisher Scientific, #89901)
following manufacturer’s instructions and were examined by western blotting probed with
ANXA2 antibody (Santa cruz #SC-28385) followed by goat anti-mouse IgG HRP-conjugated
secondary antibody (Bio-Rad #172-1011).
The full codon sequence of ANXA2 isoform 2 gene (NM_001002858.3) possessing
signal sequence and a 6x histidine tag was ligated with pLenti6/V5 vector (Invitrogen
#K495510). The ligation product was transformed into chemically competent E. coli Stbl3 cells
(Invitrogen #C737303) by a general heat shock method. E. coli transformants were selected by
ampicillin resistance and confirmed by PCR. The extracted plasmid from an E. coli transformant
was used to generate the lentivirus in combination with the packaging plasmid, psPAX2
(Addgene) and the envelop plasmid pMD2.G (Addgene) using TransIT_293 transfection reagent
(Mirus) following the same method as above. ANXA2 transduced HEK293 T/17 cells were
selected by culturing DMEM media containing 5µg/ml of blasticidin. The transduced cells were
grown in DMEM medium containing 10% fetal bovine serum, 2 mM L-glutamine and
penicillin/streptomycin in T-75 culture flasks until 50% confluency. The medium was replaced
with FreeStyle 293 expression medium (ThermoFisher Scientific, #12338018) and grown for
another 7 days. The medium was collected and filtered. Secreted ANXA2 in the culture medium
was purified by nickel chromatography and confirmed by western blotting using anti-ANXA2
antibody.

31

3.3.10

Construction of PsaA knockout strain
A clean deletion PsaA knockout T4R strain was created using the pMBSacB plasmid

(Hooven et al., 2019). Briefly, 1kb DNA segments from upstream and downstream of PsaA were
amplified. The amplified upstream and downstream PCR products were cleaned and fused by
PCR using outer primers. Both fused PCR product and pMBsacB plasmid, which is suicide
vector for site-specific mutation, were digested with BamHI and PstI restriction enzyme. The
digested flanking construct and pMBsacB plasmid were ligated and transformed into chemically
competent E. coli DH5α cells by a general heat shock method. The E. coli transformant was
selected by erythromycin resistance selection and verified by PCR. The extracted plasmid from
the E. coli transformant was transformed into S. pneumoniae strain T4R by standard S.
pneumoniae transformation procedures (Håvarstein et al., 1995). Following selection and
passage without erythromycin to allow for gene deletion recombination, pMBSacB-less PsaA
deletion mutants were selected by 15% sucrose C+Y media (Yim & Rubens, 1998). The deletion
of psaA gene was confirmed by PCR along with wild type as a control.
3.3.11

Adhesion assay and blocking assay
HEK 293 T/17 mock transduced cells and ANXA2 transduced cells (≈ 106 cells/well)

were grown in penicillin-streptomycin free culture media for 2 days until confluent in 24-well
plate. Cells were washed with serum free media to remove serum. S. pneumoniae strain T4R (≈
106 CFU/well) was incubated with both cell types for 30 min at 37°C with 5% CO2 at a
multiplicity of infection (MOI) of 1.0. Following incubation, eukaryotic cells were scraped,
transferred to microcentrifuge tube, and centrifuged at 800 rpm for 5min. Nonadherent bacteria
were removed by washing 3 times with DPBS and adherent bacteria were serially diluted and
plated on 5% sheep blood agar supplemented with 5 µg/mL of chloramphenicol. The percentage
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of adherent S. pneumoniae was determined by comparison of CFU on blood agar after the final
wash and initial number of bacteria. The assays were performed three times in triplicate.
For the competitive blocking assay, both HEK 293 T/17 mock and ANXA2 transduced
cells were initially blocked with 200 µg of recombinant PsaA (rPsaA) in PBS for 1hr at 37°C
with 5% CO2 prior to incubation with bacteria. After the incubation with bacteria the number of
adhered bacteria to human cells were determined by serial dilution and colony count.
3.3.12

Detection of binding of ANXA2 to pneumococcus by flow cytometry
S. pneumoniae strain T4R (~1x105 CFU) were resuspended in 1% BSA in PBS and

divided into 4 different groups (~2.5 x104 CFU per each group): DAPI control, secondary
antibody only control with recombinant ANXA2, both primary and secondary antibody control
without recombinant ANXA2, and recombinant ANXA2 with both primary and secondary
antibody. Each of 4 different groups were duplicated to test with 2 different concentrations of
recombinant ANXA2 (20 µg and 100 µg). The recombinant ANXA2 group was incubated with
recombinant ANXA2 on ice for 1hr and washed with 1% BSA in PBS twice by centrifugation at
13,000 rpm for 5min. Following the incubation with recombinant ANXA2, bacteria were
incubated with 1:100 diluted ANXA2 antibody (Santa Cruz Biotechnology #SC-28385) in 1%
BSA in PBS for 1hr at room temperature and washed with 1% BSA in PBS twice. The bacteria
were incubated with 1:200 diluted FITC conjugated secondary antibody for 30min at room
temperature and washed with 1% BSA in PBS twice. Fluorescent intensity was quantitated using
an Attune Acoustic Focusing Flow Cytometer (ThermoFisher Scientific) Bacterial cells were
specifically gated based on duplicate samples stained with DAPI only.
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3.3.13

Characterization of PsaA and ANXA2 binding in vitro
The biophysical interaction of PsaA and ANXA2 were investigated using two different

approaches: analytical size exclusion chromatography (SEC) and circular dichroism (CD)
spectroscopy. For SEC, samples were prepared in PBS, and dithiothreitol (DTT) was added to a
final concentration of 2 mM to reduce any oxidized disulfide dimers. The absence of dimers was
later confirmed by running a non-reducing SDS-PAGE gel. The initial sample for SEC contained
a 1:1 ratio of PsaA:recombinant ANXA2 expressed in E. coli and PsaA:ANXA2 expressed in
HEK293 T/17 cells where each protein concentration was 0.18 mg/ml. The individual proteins
and the protein mixtures were incubated for 1 hour at either 25 °C or 37 °C prior to analysis.
Validation of PsaA – ANXA2 interactions was carried out using a Superdex 200 10/300 GL
column connected to an AKTA Purifier 10 system at room temperature. Prior to the analysis, the
column was equilibrated with two column volumes of PBS containing 2 mM DTT. A needle
syringe was used to load 150 µL of the protein mixture into a 100 µL sample loop, and 100 μL
was injected on to the column. The column was run at a flow rate of 0.5 mL/min according to the
manufacturer’s specifications.
The CD measurements were carried out using a Jasco 1500 CD spectrometer at 25 °C.
The measurements were performed using a 1 mm pathlength quartz cuvette. Protein solutions
were made containing 0.12 mg/ml of each protein, and mixtures contained a 1:1 ratio of PsaAand
ANXA2 (E. coli) or ANXA2 (HEK293/T17), with each protein at 0.12 mg/ml concentration.
The buffer for all solutions was 10 mM sodium phosphate (pH 6.5). Far-UV spectra were
collected between 180 to 260 nm, with the scan rate set at 10 nm/minute at a bandwidth of 1 nm
using 4 s as the integration time. All spectra were smoothed using Savitzky-Golay filter set to a
window size of 17.
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3.3.14

PsaA and ANXA2 binding assay
Recombinant PsaA protein was covalently attached to AminoLink Plus beaded agarose

resin (ThermoFisher Scientific, #20394) following manufacturer’s instructions and modified
protocol from a previous study (Lapetina & Gil-Henn, 2017). For some samples, 5mM of
manganese sulfate was added to PsaA-beads and incubated at 4°C for 30 minutes by end-overend rocking to investigate if additional manganese affects binding. As a control, BSA was
covalently attached to resin and each bead was blocked with 50mM NaCNBH3 for 30 minutes by
end-over-end rocking after incubation with either PsaA or BSA. Control beads were blocked
with 50mM NaCNBH3 without the incubation with any proteins. The four different agarose
beads: PsaA-bead, PsaA (Mn)-bead, BSA-bead, no protein-bead were incubated with ~50 µg of
recombinant ANXA2 and BSA at 37°C for 1 hr, respectively. After incubation, beads were
washed with PBS twice by centrifugation at 8000xg for 5 minutes. The remaining buffer was
removed by 27G x ½ needle attached to 1ml syringe. The binding between bait and prey protein
was disrupted by 40µl of 2x Laemmli sample buffer (BioRad, #161-0737). The samples were
heated at 95°C for 10 minutes and centrifuged at 13,000 rpm for 5 minutes. The supernatant was
loaded onto an SDS-PAGE gel and binding of ANXA2 to PsaA was confirmed by western
blotting using anti-ANXA2 antibody.
3.3.15

Statistics
For adhesion assays, values from three or more experiments were compared by an

unpaired, two-tailed Student’s t-test to test for statistical significance using GraphPad Prism
version 9.0.0 for Windows (GraphPad Software, San Diego, California USA,
www.graphpad.com). A P value less than 0.05 was considered significant.
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3.4

Results

3.4.1

Identification of host cellular receptor for PsaA
To determine protein interactions of PsaA with human pharyngeal epithelial cells, whole

cell lysate proteins from Detroit 562 cells were separated by SDS-PAGE, followed by
transferring to a PVDF membrane which was probed with biotinylated PsaA bait protein in a farwestern blot assay. The specific interaction of PsaA with whole cell lysate proteins from Detroit
562 cell was visualized by HRP-conjugated streptavidin. A strong band was visualized at
approximately 35 kDa (Figure 3.1A). Additional bands at approximately 90 kDa and fainter band
at approximately 115 kDa were ruled out from further investigation since these were routinely
visualized on control blots only with HRP-conjugated streptavidin. To identify potential
receptors of PsaA, whole cell lysate proteins from Detroit 562 cells were further separated by
2DE, followed by far- western blot analysis. A very strong signal was observed at approximately
35 kDa. Mass spectrometry analysis identified 27 peptides. Based on isoelectric point and
molecular weight, peptide coverage and probability score, human annexin A2 (ANXA2) was
identified as a putative receptor of PsaA (Figure 3.1B). As a control, biotinylated HRP alone was
used to probe a replicate membrane and no chemiluminescent signal was detected (data not
shown).
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Figure 3.1

Far-western blotting of human nasopharynx cell and PsaA.

(A) SDS-PAGE of whole cell lysate of human nasopharynx cell (Detroit 562) was probed with
biotinylated PsaA. (B). Far- western blot analysis of whole cell lysate proteins of human Detroit
562 cell probed with biotinylated PsaA. A specific interaction between PsaA and whole proteins
was detected by a streptavidin bead conjugated with HRP and visualized by x-ray film exposure.
A protein spot from approximately 35 kDa (arrow) was excised from Coomassie stained gel and
analyzed by electrospray ionization-tandem mass spectrometry for protein identification. Based
on isoelectric point and molecular weight summarized in the table, human annexin A2 was
identified as a putative receptor of PsaA. Amino acid sequences of human ANXA2 identified
from mass spectrometry were underscored.

3.4.2

ANXA2 expression in the murine respiratory tract
Annexin A2 is expressed in a variety of tissues including respiratory epithelium. Results

from Figure 2 demonstrated that Detroit 562 nasopharyngeal cells express ANXA2. To ensure
this was not an artifact of immortalization and to evaluate relative expression throughout the
respiratory tract, tissue from the nasopharynx, bronchi, lungs, and heart (as a control) were
isolated from mice and subjected to western blot probing for ANXA2. A band of approximately
37 kDa corresponding to ANXA2 was highly expressed in the bronchi and lung and to a lesser
degree in the nasopharynx, but not in heart tissue (Figure 3.2A).
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Annexin A2 expression throughout the murine tissues were also detected by
immunohistochemistry. The expression of ANXA2 was detected in multiple cell types and
locations of lung. Within the bronchi and bronchioles there was multifocal staining of the apical
membrane of the epithelial cells. Vascular endothelial cells of small to medium sized vessels
were diffusely positive but no staining was shown in cardiomyocytes. Within the interstitium and
alveoli, macrophages have cytoplasmic staining. The mesothelial cells along the visceral pleura
were diffusely positive (Figure 3.2B).
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Figure 3.2

Expression of ANXA2 in murine respiratory tissues.

(A) Tissues samples from the nasopharynx, bronchi, lung, and heart were collected from
C57BL/6 J mice. Expression of ANXA2 in tissue homogenates were analyzed by western blot.
(B) ANXA2 Immunohistochemical staining in murine lung and heart. (a) Within the lung
staining was present along the apical surface of epithelial cells within bronchi and bronchioles
(arrows) and rare type I pneumonocytes (asterisk). (b) Endothelial cells of small to medium sized
vessels were diffusely positive (arrows). (c) Interstitial and alveolar macrophages (asterisks) had
cytoplasmic staining and mesothelial cells along the visceral pleura of the lung were diffusely
positive. (d) Within the heart staining was localized to vascular endothelial cells and visceral
mesothelial cells (arrows), with no staining of cardiomyocytes. (e) Negative control. Bar = 50
μm.
3.4.3

ANXA2 transduced eukaryotic cells
To verify the interaction of PsaA with ANXA2, we sought to express ANXA2 in naïve

HEK293 T/17 cells using a lentiviral expression system. Expression of ANXA2 was assessed by
western blotting using anti-ANXA2 antibody. As shown in Figure 3.3A, little to no expression
was observed from HEK293 T/17 cells transduced with empty lentiviral expression vector, while
HEK293 T/17 cells transduced with pLenti-ANXA2 expressed ANXA2 of greater molecular
weight than Detroit 562 cells (human nasopharyngeal) and A549 (human alveolar) epithelial
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cells. This is presumably due to addition of a MYC/DDK tag and multiple cloning site in pLentiANXA2. As a control, the PVDF membrane was probed with the secondary antibody only and
no signal was detected (Figure 3.3B).

Figure 3.3

Western blot probed with murine anti-ANXA2 monoclonal antibody.

(A) Four different cell lines (Detroit 562, A549, HEK 293 T/17 mock, and ANXA2 transduced
HEK 293 T/17) were probed with ANXA2 antibody to detect the ANXA2 expression. Size
difference could be due to lentiviral expressed plasmid containing Myc-DDK tag and multiple
cloning regions. (B) Secondary only antibody control western blotting to confirm the nonspecific
signal. (C) The purified ANXA2 by nickel chromatography from cell culture medium of ANXA2
transduced HEK293 T/17 cells.
To further investigate the interaction of PsaA with ANXA2 in vitro, we expressed
another version of ANXA2 in naïve HEK293 T/17 cells using a lentiviral expression system that
can secrete ANXA2 out to culture media for purification (Figure 3C).
3.4.4

Effect of ANXA2 on colonization by pneumococcus
Since PsaA is known to promote adherence of pneumococcus to the human nasopharynx,

we assessed the adherence of capsule null strain T4R to HEK293 T/17 cells transduced with
ANXA2 and HEK293 T/17 mock transduced cells. T4R strain showed approximately 3.21 ±
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0.76 % adherence to HEK293 T/17 cells transduced with ANXA2, which was significantly
higher than that of HEK293 T/17 mock transduced cells (1.23 ±0.55) (Figure 3.4A). However, a
ΔPsaA T4R isogenic mutant bound equally to mock and ANXA2 transduced cells (Figure 3.4B).
To confirm that the specific interaction of PsaA with ANXA2 is responsible for the
increased adherence of T4R to HEK293 T/17 cells transduced with ANXA2, we preincubated
cells with recombinant PsaA, prior to incubation with S. pneumoniae T4R. Adherence of T4R to
HEK 293 T/17 cells transduced with ANXA2 was significantly reduced by preincubation with
PsaA, whereas adherence of T4R mock transduced cells was not (Figure 3.4C).
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Figure 3.4

Binding of S. pneumoniae T4R to HEK 293 T/17 expressing ANXA2.

HEK 293 T/17 expressing ANXA2 or Mock cells were incubated with S. pneumoniae T4R wild
type (A) and at MOI of 1 for 30 min. After washing, the numbers of S. pneumoniae T4R bound
to HEK 293 T/17 cells were determined by plate counts (B) T4R ΔPsaA at MOI of 1 for 30 min.
After washing, the numbers of S. pneumoniae T4R bound to HEK 293 T/17 cells were
determined by plate counts. (C) To determine the effect of blocking ANXA2 on binding of S.
pneumoniae T4R to HEK 293 T/17 expressing ANXA2, HEK 293 T/17 expressing ANXA2 or
Mock cells were incubated with recombinant PsaA (200 μg/ml) for 60 min. After washing, the
numbers of S. pneumoniae T4R bound to HEK 293 T/17 cells were determined by plate counts.
Experiments were performed three times in triplicate. Data shown are the mean ±SD. Asterisk
indicates the statistical significance of student t-test at P < 0.05.
To further confirm binding of ANXA2 with pneumococcus, strain T4R was incubated
with 20 µg or 100 µg of recombinant ANXA2. The binding of ANXA2 to pneumococcus was
quantitated by flow cytometry after incubation with ANXA2 antibody, followed by fluorescein
conjugated secondary antibody. As shown in Figure 3.5, the binding of ANXA2 to
pneumococcus increased in a dose dependent manner. Combined, these results demonstrate that
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PsaA binds to ANXA2 and this interaction can promote pneumococcal adherence to human
nasopharyngeal cells.

Figure 3.5

Binding of recombinant ANXA2 to S. pneumoniae T4R.

A recombinant ANXA2 20 μg (A) or 100 μg (B) was incubated with S. pneumoniae T4R,
followed by incubation with fluorescein isothiocyanate-conjugated anti-ANXA2 antibody.
Binding of ANXA2 to S. pneumoniae T4R was assessed by flow cytometry. As a control, S.
pneumoniae T4R was incubated with fluorescein isothiocyanateconjugated anti-ANXA2
antibody. Percentages shown are percent of the total population positive for FITC as compared to
secondary only antibody control with each different amount of recombinant ANXA2. Data are
representative of at least three replicate experiments.
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3.4.5

Biophysical Measurements of PsaA:ANXA2 Binding
To characterize the interaction of PsaA and ANXA2 in vitro, we performed analytical

size exclusion chromatography (SEC). SEC can be used for determining the molecular mass of
proteins and separating them under native conditions (Whitaker, 1963). Since this technique is
largely based on protein identification by size, it can be used to analyze protein – protein
interactions (Bloustine et al., 2003; Stevens, 1989). Proteins upon interacting with each other
tend to form large complexes of varying stabilities. Therefore, based on the elution profile of the
individual proteins, any elution peaks of higher molecular mass can be easily identified. All three
proteins: PsaA, ANXA2 (E. coli), and ANXA2 (HEK293 T/17) have similar molecular masses,
and the SEC peaks had correspondingly similar elution profiles (Figure 3.6). This profile did not
change when proteins were incubated separately for 1 hr at either 25 °C or 37 °C. Each isolated
protein eluted at a volume consistent with its monomeric molecular weight on the calibrated SEC
column.
Mixtures were then prepared for a 1:1 ratio of PsaA and ANXA2 (E. coli) or ANXA2
(HEK293 T/17). After incubation at 25 °C for 1 hr, the elution profile at 280 nm for the protein
mixture of PsaA and ANXA2 (E. coli) as well as PsaA and AXA2 (HEK293 T/17), is largely the
sum of the elution profile for the individual, isolated proteins (Figure 3.6A,B). No significant
evidence is seen for new, higher molecular weight species eluting at earlier times/volumes. This
changes significantly when the proteins were incubated for 1 hr at 37 °C, where a significant
leading edge is now observed (Figure 3.6C, D). When the association is strong and the
dissociation rate is slow, an additional, well defined elution peak at early elution volume is
expected. This peak would correspond to the protein-protein complex (Kirkwood et al., 2013).
However, if the complex undergoes exchange between the free and bound form during the
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course of the experiment (30 minutes), a broad shoulder is expected, as seen here. Under the
appropriate circumstances, this shoulder can be interpreted quantitatively to determine an
exchange rate (Bao et al., 2014; Norma J. Greenfield, 2006) and analytical ultracentrifugation
(AUC) would be more appropriate for determining thermodynamic parameters (Cole et al.,
2011). Here, we simply demonstrate that the proteins shift to higher molecular weight species
upon incubation with heating.
To assess possible structural changes upon binding, we performed circular dichroism
(CD) spectroscopy on the proteins and their mixtures. CD is typically used to determine
secondary structure of proteins and any change in secondary structure can be observed for
proteins that interact with small molecules such as peptides or nanoparticles (Lindsey R. Brown
et al., 2016; Norma J Greenfield, 2006; Somarathne et al., 2021). Secondary structure profiles for
both PsaA and ANXA2 looked similar, indicating a high proportion of alpha helices, and this
aligns well with their crystal structures (Figure B.2A,B) (Lawrence et al., 1998; Shao et al.,
2006). To investigate the secondary structure changes in the protein complex, we mixed the
proteins in a 1:1 ratio and incubated for 1 hr at either 25 °C or 37 °C. The CD spectrum of this
mixture exhibited only very minor changes from the summed spectra of the individual proteins
(Figure B.2, green vs. purple curves). Significant changes in the CD spectra are expected if one
of the proteins is partially folded or becomes unfolded, but that does not appear to occur.
Nevertheless, the CD spectra observed are not consistent with unfolded or disordered mixtures of
protein; therefore, the SEC data (Figure 3.6) most likely does not originate from an anomalous,
soluble aggregate. Instead, the interaction observed in SEC more likely represents a fastdissociating stable complex where the secondary structures of PsaA and ANXA2 are largely
retained.
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Figure 3.6

Size-exclusion chromatography (SEC) of PsaA (blue), ANXA2 (red) and the 1:1
mixture (green) of both proteins.

(A) SEC was performed with PsaA, ANXA2 (HEK293 T/17), and a 1:1 mixture after incubating
each for 1 hr at 25°C respectively. (B) Data was performed with PsaA, ANXA2 (E. coli), and a
1:1 mixture after incubating each for 1 hr at 25°C respectively. (C, D) Same proteins as (A)
and (B), but incubation occurred for 1 hr at 37°C. The long leading edge in panels (C) and (D)
likely originates from fast exchanging, interacting species following incubation.
3.4.6

Binding of ANXA2 to PsaA
We investigated the direct binding interaction between recombinant ANXA2 and PsaA

proteins. The N-terminus of recombinant PsaA was covalently bound to aldehyde groups of
agarose beads and reduced by sodium cyanoborohydride which form stable secondary amine
bonds. PsaA-loaded beads were incubated with either recombinant ANXA2 or BSA (control)
and following washes, interactions determined by SDS-PAGE gel Coomassie staining and
western blot. Recombinant ANXA2 could bind minimally to both BSA-beads and no proteins46

beads, (Figure 7, lanes 3 and 4), which indicates incomplete blocking of beads or that washing
was not completely effective (Figure 7A). However, stained SDS-PAGE gel and western blot
clearly indicates that binding of ANXA2 to PsaA beads was significantly greater than control
beads. Similar amounts of BSA bound all 4 different beads and indicated that binding of ANXA2
to PsaA was specific (Figure 3.7).

Figure 3.7

Direct binding interaction between recombinant ANXA2 and PsaA.

The bound recombinant ANXA2 or BSA to protein-bound beads or no proteins-beads were
separated on SDS-PAGE gel and stained with Coomassie blue G-250 (A) and replicated gel
was transferred to PVDF membrane and probed with anti-ANXA2 antibody (C-10) by western
blot (B). Bound ANX2 to PsaA-beads (lane 1), bound ANXA2 to PsaA (Mn)-beads (lane 2),
bound ANXA2 to BSA-beads (lane 3), bound ANXA2 to no proteins-beads (lane 4), bound BSA
to PsaA-beads (lane 5), bound BSA to PsaA (Mn)-beads (lane 6), bound BSA to BSA-beads
(lane 7), and bound BSA to no proteins-beads (lane 8).
3.5

Discussion
Streptococcus pneumoniae is a common colonizer of the nasopharynx and can cause

respiratory infection and invasive diseases such as bacteremia, meningitis primarily in children
younger than 3 and the elderly (Koliou et al., 2018). Additionally, the mortality of children under
the age of 5 is higher in developing countries. Since the current pneumococcal vaccines (PCV13,
PPSV23) have been licensed, pneumococcal invasive disease has been effectively reduced and a
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previous case study showed that these vaccines have an effectiveness of 96% in healthy children
(Whitney et al., 2006). However, the most recent vaccine, PPSV23, can only provide protection
against 23 of approximately 100 serotypes. Also, several studies indicate that previously
common pneumococcal serotypes have been replaced by nonvaccine serotypes (Huang et al.,
2005; Weinberger et al., 2011). Consequently, many groups are studying protein-based vaccines
that could provide a universal immune response to all the different pneumococcal serotypes. The
candidate antigens for protein-based vaccine should be genetically conserved to provide broad
coverage over different serotypes (Mehr & Wood, 2012). Also, protein antigen candidates should
be expressed during pathogenesis and reduce colonization of pneumococcus below levels that
can result in pneumococcal disease (Pichichero et al., 2016). Thus, selection of target proteins for
protein-based vaccines is essential and such targets should ideally prevent both invasive and noninvasive pneumococcal colonization and diseases. There are currently numerous candidates for a
protein-based pneumococcal vaccine, including proteins of the histidine triad protein family,
PhtD and PhtE, which are surface exposed proteins and expressed in most of pneumococcal
strains. A previous study indicated that these proteins could elicit CD4 T cell memory responses
against colonization in mice (Khan & Pichichero, 2013). The choline binding surface protein,
PcpA, was also shown to elicit serum antibody response during pneumococcal lung infection and
colonization (Kaur et al., 2011). One of the most important virulence factors of pneumococcus,
pneumolysin, is also an attractive candidate for eliciting host immunity and detoxified
pneumolysin produces protective, pneumolysin-neutralizing antibodies (Salha et al., 2012).
Pneumococcal colonization is prerequisite to the develop the pneumococcal infection.
The human nasopharynx is the primary colonization site for pneumococcus and multiple proteins
are involved in colonization and adherence to host cells. These include PhtD, choline binding
48

protein A (CbpA orPspC), surface exposed lipoproteins foldase protein (PrsA), adhesion and
virulence protein A (PavA) and PsaA (Kadioglu et al., 2008; Weiser et al., 2018). Previous
studies indicated interaction between host cellular receptors and some of pneumococcal proteins
that are known to be involved in colonization: polymeric immunoglobulin receptor and laminin
receptor for CbpA and fibronectin for PavA (Kadioglu et al., 2008; Orihuela et al., 2009; Zhang
et al., 2000).
Although pneumococcal adhesin proteins have been well characterized, relatively little is
known regarding their host cellular receptors. Thus, our group has focused on identification of
host cellular receptors for pneumococcal adhesin proteins. PsaA is known as an ABC transporter
for manganese. Gram-positive bacteria utilize numerous ABC transporters and lipoproteins to
uptake metal ions and other metabolites from the environment. These transporters are also often
involved in adhesion and pathogenesis. Previous work by our group and others demonstrated that
proteins involved in zinc homeostasis can impact colonization and biofilm formation (Bayle et
al., 2011; Brown et al., 2017; Lindsey R Brown et al., 2016; Plumptre et al., 2014). Given its role
in Mn2+ acquisition, as well as involvement in adhesion, PsaA has also been identified as an
important vaccine target.
To identify host cellular receptors for PsaA, we performed far-western blot analysis and
identified ANXA2 as a candidate receptor of PsaA. Lentiviral expression of ANXA2 in HEK293
T/17 cells significantly increased adherence of T4R strain and recombinant PsaA or ANXA2
inhibited adherence of T4R strain. These results clearly demonstrated that ANXA2 is a receptor
for PsaA. AnnexinA2 is a member of calcium-dependent phospholipid binding proteins that play
a role in multiple cellular processes such as exocytosis, endocytosis, membrane organization, and
ion channel conductance (Bharadwaj et al., 2013). ANXA2 has been shown to be involved in
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efficient bacterial invasion of epithelial cells by pathogens such as Rickettisa, Mycoplasma
pneumoniae, and Pseudomonas aeruginosa (Kirschnek et al., 2005; Somarajan et al., 2014). In
addition to our findings, another group also demonstrated that pneumococcal surface protein K
(PspK) interacts with ANXA2 and promotes adherence to lung epithelial cells (Jang et al., 2017).
Furthermore, a previous study demonstrated that PsaA also interacts with E-cadherin expressed
on nasopharyngeal epithelial cells (Anderton et al., 2007). While our 2-D far-western analysis
did not identify E-cadherin as interacting with PsaA, a faint band of approximately 120kDa was
seen in our 1D far-western blot (Figure 1), which may correspond to E-cadherin. These results
demonstrated a single pathogen adhesion protein can interact with multiple host receptors and
vice versa. To our surprise, the adherence of a PsaA-null mutant to nasopharyngeal epithelial
cells was significantly increased compared to wild type T4R. We are currently investigating why
loss of PsaA would increase pneumococcal adhesion to the epithelial surface. A potential
explanation is that PsaA could mask other pneumococcal adhesins as was shown for surface
protein G (SasG) of S. aureus masking the binding of S. aureus clumping factor B (ClfB) to
cytokeratin of host cell (Corrigan et al., 2007). Additionally, we have previously shown that loss
of proteins involved in metal acquisition can impact expression of numerous pneumococcal
surface proteins including known and predicted adhesins (Lindsey R Brown et al., 2016).
Given the high expression of ANXA2 in bronchial epithelial cells and interaction with
multiple bacterial adhesion proteins, ANXA2 might be the common receptor exploited by
respiratory pathogens to establish colonization. We will continue to investigate the role of
ANXA2 in pneumococcal pathogenesis in vivo. This result can imply that ANXA2 can be a
common receptor for multiple pneumococcal proteins.
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CHAPTER IV
PROTEOMIC PROFILING OF PLANKTONIC AND BIOFILM FORMATION PROTEINS
AND THEIR ABILITY IN COLONIZATION
4.1

Abstract
Streptococcus pneumoniae (pneumococcus) is a colonizer of the human nasopharynx

capable of causing invasive disease. The human nasopharyngeal environment has limited
nutrients and lower temperature than normal body temperature. This unique environment allows
pneumococcus form biofilms and allows for enhanced genetic exchange. In this study, we
utilized 2DE SDS-PAGE analysis to investigate proteomic comparisons between planktonic and
biofilm membrane proteins. We identified that lipoprotein of oligopeptide transporter (AmiA)
and lipoprotein of methionine transporter (SP_0148) were overexpressed during biofilm
formation. Deletion of these two genes decreased biofilm formation. Especially, the SP_0148
mutant showed less adherence to human nasopharyngeal epithelial cells (Detroit 562). These
results suggest that there are key proteins in biofilm formation and likely play an important role
in colonization.
4.2

Introduction
Streptococcus pneumoniae (pneumococcus) is a common gram-positive colonizer

capable of causing invasive disease such as meningitis, sepsis, and pneumonia resulting in over 1
million deaths of young children each year (Bogaert et al., 2004). Even when non-invasive, S.
pneumoniae is one of the common causes of acute otitis media in young children, and treatment
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costs $2 billion to $5.3 billion in U.S (Eskola et al., 2001). Pneumococcus is part of the normal
commensal bacteria of nasopharynx and most often asymptomatic. Invasive disease can be
caused by invasion from the nasopharynx to lung to cause pneumonia, by invasion into the blood
resulting in bacteremia, and by crossing the blood-brain barrier to cause meningitis (Sleeman et
al., 2006). Therefore, colonization is prerequisite to invasive disease (Bogaert et al., 2004).
When pneumococci colonize, they have differences in growth rate, metabolism, gene
expression, and protein production compared to planktonic cells. Additionally, mature biofilms
can enhance antibiotic resistance and evade host immune defense systems (Jensen et al., 2010).
Biofilm formation is known to depend upon expression of specific surface proteins (Marks,
Parameswaran, et al., 2012). A previous study identified lung and brain isolates had increased
expression of genes that were involved in biofilm formation such as neuraminidase-coding genes
(nanA, SP_1693 and nanB, SP_1687), competence genes (comA, SP_0042 and comX, SP_0014)
and the virulence gene regulator (mgrA, SP_1800) (Oggioni et al., 2006). Pneumococcus can
also communicate with other bacterial cells through quorum sensing to form successful biofilms.
One of the quorum sensing mechanisms is dependent on the metabolic enzyme, LuxS, which
synthesizes the autoinducer-2 (Joyce et al., 2004). S. pneumoniae and other bacterial species
including Staphylococcus intermedius, Streptococcus oralis, Streptococcus gordonii, and
Streptococcus mutans utilize autoinducers to communicate with neighboring cells and to regulate
gene expression in response to environmental and cell density changes (Kaper & Sperandio,
2005). A previous study showed that a D39 luxS mutant formed 80% less biofilm than wild type
and a complemented strain could recover biofilm formation to levels of the wild type strain
(Vidal et al., 2011). An additional quorum sensing mechanism is related to a peptide pheromone
(CSP) based system. CSP is encoded by comC and exported by the ABC transporter, ComAB.
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The secreted CSP is sensed by a two-component signal transduction system composed of ComD
and its response regulator, ComE which activates its own operon comCDE and ComX. A sigma
factor, ComX, activates other competence genes which enable DNA uptake and recombination
(Peterson et al., 2004). The competence system can enhance the stability of pneumococcal
biofilms. As shown in a previous study, addition of CSP could stimulate the formation of stable
biofilms after 24 hours (Trappetti et al., 2011).
When pneumococci colonize in human nasopharynx, they encounter lower temperature
(34℃) than normal body temperature, limited nutrients, and interactions with epithelial cells.
This unique nasopharyngeal environment can enhance biofilm formation and induce competence
genes (Marks, Reddinger, et al., 2012). Some pneumococcal proteins are anchored to the cell
wall and exposed to the surface which allow proteins to interact with host cells (Pérez‐Dorado et
al., 2012). Furthermore, the mature biofilms in human nasopharynx express about 30% different
proteins compared to planktonic cells. These expressed proteins are candidates for protein-based
vaccines and include serine-rich repeat protein (PsrP) and choline binding proteins (CbpA)
(Sanchez et al., 2011).These protein-based vaccines candidates such as choline binding proteins
are found in all pneumococcal serotypes and shown to be able to protect against pneumococcal
infection (Sempere et al., 2021). Thus, in this study we identified the proteins differentially
expressed between pneumococcal planktonic growth that represents invasive conditions and
mature biofilms formed at low temperature that mimic colonization. We hypothesized that
proteins specifically expressed during biofilm formation can be involved in colonization and
potentially play a role as adhesins.
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4.3
4.3.1

Materials and Methods
Strain and bacterial growth conditions
The unencapsulated TIGR4 derivative strain, T4R, were grown planktonically and as

biofilms that can mimic invasion and colonization states of pneumococcus in humans
respectively. For planktonic growth 1x105 CFU/ml of T4R were inoculated in 50ml of 1:2
diluted (50%) Todd Hewitt (TH) medium and grown to mid-logarithmic phase (O.D.600nm 0.6)
in 37℃ water bath. For the biofilm growth, same number of bacteria were grown in 50% TH
medium at 34℃ with 10% CO2 for 2 days. Each 50ml biofilm culture was grown in 9 plates. The
day following inoculation, medium was replaced with fresh 50% TH medium. After 2 days, each
plate was washed with PBS and biofilm was collected by cell scraper. Both planktonic and
biofilm cells were collected by centrifugation at 13,000 rpm for 10 min. Each pellet was stored at
-80℃ to extract the proteins.
4.3.2

Extraction and fractionization of proteins
Both pellets of planktonic and biofilm bacteria were suspended in 20ml of sterilized

distilled water and placed in a French press for lysis. The suspension of pellet was lysed through
the French press operated at 18,000 lb/in2 with the high-ratio for 30 min as described in previous
study (Wingfield, 2014). The soluble proteins (cytoplasm portion) were collected by
centrifugation at 13,000 rpm for 30 min. After centrifugation, pellets of planktonic and biofilm
bacteria were lysed with 500µl of rehydration buffer (7M urea, 2M thiourea, 0.5% triton X-100,
2mM TBP) to fractionize in-soluble proteins (membrane portion) for 5 hours at room
temperature with shaking. The membrane proteins were collected by centrifugation at 13,000
rpm for 10 min after lysis with rehydration buffer. The pellet was lysed with mutanolysin for 1
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hour at 37℃ to fractionize cell wall proteins (Morsczeck et al., 2008). The mutanolysin lysate
was precipitated with ice-cold acetone.
4.3.3

2DE and identification of planktonic and biofilm proteins
Planktonic and biofilm membrane proteins were quantified using protein assay kit

(Thermofisher, 22660) following manufacturer’s protocol and 50µg of each proteins were
separated by 12.5% SDS-PAGE gel using 2DE 3-11 non-linear pH gradient 7 cm IPG Drystrip
(GE Healthcare, #GE17-6003-73). The Drystrip was allowed to rehydrate at room temperature
overnight. The overnight rehydrated Drystrip was ran following manufacturer protocol: 200V
1min, 3500V 1hour 30min 2.8kVh, 3500V 1hour 5min 3.7kVh. The Drystrip gel was
equilibrated and separated by 12.5% SDS-PAGE gel as previously described (Hu et al., 2021).
After electrophoresis, the polyacrylamide gel was stained with R-250 Coomassie blue overnight.
On the following day, Coomassie blue stained gel was destained with destaining solution (10%
methanol, 10% acetic acid, 80% water) and the 2 different gel images were overlayed to compare
which biofilm proteins were overexpressed during biofilm formation.
4.3.4

Trypsin in gel digestion and mass spectrometry
The overexpressed proteins were selected from 2DE biofilm gel and each spot was

excised from the Coomassie blue stained gel in 1mm cubic size and transferred to 1.7ml
microtube (Axygen, cat. 311-04-051). The excised gel was agitated in 500µl of destaining
solution (20% v/v methanol, 20% v/v acetic acid) for 2 hours and solution was replaced with
second destaining solution (50% v/v methanol, 5% v/v acetic acid) for overnight. On following
day, the destaining solution was replaced with 200µl of fresh destaining solution and agitated
until there is no sign of remaining Coomassie blue stain. The gel pieces were agitated with 200µl
56

of 100% acetonitrile for 5 min. The acetonitrile was discarded and agitated with 200µl of 50%
v/v acetonitrile in 50mM ammonium bicarbonate and for 1 hour. To reduce the proteins, 50µl of
10mM DTT in 100mM ammonium bicarbonate was added and agitated for 30 min. The solution
was replaced with 200µl of 50mM iodoacetamide in 100mM ammonium bicarbonate and
agitated for 30 min. The gel pieces were washed with 200µl of 100mM ammonium bicarbonate
for 10 min. The gel pieces were dehydrated in 200µl of 100% acetonitrile for 5 min with
agitation. The solution was replaced with 100µl of 100mM ammonium bicarbonate to rehydrate
for 10 min with agitation. The gels were dehydrated in 200µl of 100% acetonitrile for 5 min with
agitation. The solution was replaced with fresh 200µl of 100% acetonitrile. The gel was dried by
vacuum centrifugation. One µg of MS grade trypsin (Promega, cat. V5073) stock in 50µl of
50mM acetic acid was added for digestion and incubated on ice for 10 min. The excess trypsin
stock solution was discarded and added 20µl of 50mM ammonium bicarbonate and incubated at
37℃ overnight. On the following day, the trypsin digested peptides were collected by adding
30µl of extraction buffer (50% v/v acetonitrile, 5% v/v formic acid) twice. Peptide mass spectra
were generated using MALDI- TOF/TOF (ABI4700) and protein identification was performed
using ABI GPS Explorer software V3.5.
4.3.5

Quantitation of RNA transcripts
For quantitation of each T4R planktonic and biofilm gene transcripts, T4R planktonic

was grown in 3ml of 50% TH media to O.D.600nm of 0.5 and biofilm was grown in 20ml of 50%
TH media at 34℃, 10% CO2 for 2 days. Each pellet of planktonic and biofilm was washed in
1ml of ice-cold PBS and collected by centrifugation. The pellets were resuspended in 400µl of
RLT buffer (Qiagen, 74106) containing 1% v/v of beta-mercaptoethanol and lysed by sonication
and, bead beating protocol as described in previous study and RNA was extracted from lysates
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by using Qiagen RNaesy mini kit (Burcham et al., 2018). Both planktonic and biofilm RNA was
quantitated using Qubit dsDNA HS assay kits (Thermofisher, Q32851) and Qubit RNA BR assay
kits (Thermofisher, Q10210) following manufacturer’s instructions. For cDNA synthesis, 5µg of
each RNA was used in 20µl reaction using Maxima first strand cDNA synthesis kit
(Thermofisher, K1641). The synthesized cDNA and control without reverse transcriptase were
diluted 1:10 and 1µl of diluted samples were used in total of 15µl qRT-PCR reaction. The
amplicons were detected by SYBR Green (Applied Biosystems, 4309155).
4.3.6

Construction of AmiA and SP_0148 knockout strain
The isogenic mutants of AmiA and SP_0148 were constructed from the unencapsulated

T4R strain by splicing by overlap extension (SOE) PCR method as previously described
(Lindsey R Brown et al., 2016). One kbp of upstream and downstream of gene was amplified
and gene of interest was replaced by erythromycin resistance cassette. Gene deletions were
confirmed by PCR compared to the wildtype strain.
4.3.7

Crystal violet biofilm assay
Crystal violet biofilm assay was performed in 6-well plates. T4R and its isogenic mutants

lacking AmiA and SP_0148 were diluted to a concentration of 1x105 CFU/ml in 50% TH
medium and 2ml were added to a 6-well plate. They were incubated in same manner above.
Following incubation, bacteria were washed with PBS and stained with 0.2% crystal violet
solution for 10 min. After crystal violet staining, cells were washed with PBS twice and air dried.
Crystal violet was solubilized with 100% ethanol for 15 min and 200µl was transferred to a 96well plate (Shukla & Rao, 2017). The plate was read in a BioTek spectrophotometer at O.D.540nm.
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4.3.8

Impact of media and mutation on growth conditions
Growth curves were performed in 3 different media: 50% TH, Todd Hewitt

supplemented with yeast extract (THY), and C+Y for 3 different T4R strains: T4R, the AmiA
mutant, and the SP_0148 mutant. Bacteria were diluted to 1x105 CFU/ml and 200µl of each
strain was inoculated to 96-well plate. Plate was incubated at 34℃ and read at OD600 nm every
1hr for 48hr.
4.3.9

Adhesion assay and blocking assay
The human nasopharyngeal epithelial cell line, Detroit 562, was seeded at 1x106

cells/well in penicillin-streptomycin free EMEM (ATCC, 30-2003) culture medium for 2 days
until they formed complete monolayer in 24-well plate. After 2 days, Detroit cells were
trypsinized and quantitated by hemacytometer cell count method. Prior to incubation with T4R
strains, wildtype and mutant strains were grown in 10ml of C+Y media to mid-logarithmic phase
(O.D.600nm 0.4) in 37℃ water bath. One milliliter of each strain was transferred to tube and
centrifuged. The pellet was suspended in 1ml of penicillin-streptomycin free EMEM medium
and diluted in 1:100. The confluent Detroit 562 cells were incubated with S. pneumoniae strain
T4R, T4R AmiA mutant, or T4R SP_0148 mutant at multiplicity of infection (MOI) of 1.0
(2x106 cells:2x106 CFU) at 37℃ with 5% CO2. After 30 min incubation, nonadherent bacteria
were removed by washing 3 times with DPBS. The cells were trypsinized for 5 min and adhered
bacteria were serial diluted and plated on 5% sheep blood agar for CFU quantitation. Each assay
was performed in triplicate at least three times.
The Detroit 562 cells were pre-blocked with 200µg of recombinant AmiA or SP_0148, or
both proteins for 1 hr at 37℃ prior to incubation with T4R. After pre-blocking, proteins were
removed, and the cells were incubated with bacteria for 30 min at 37℃ with 5% CO2 in same
59

manner above. After the incubation, cells were washed 3 times with DPBS and adhered bacteria
were quantitated as described above. The assays were performed in triplicate at least three times.
4.3.10

Statistics
For adhesion and blocking assays and crystal violet biofilm assays, values from three or

more experiments were compared by an unpaired, two-tailed Student’s t-test to test for statistical
significance using GraphPad Prism version 9.0.0 for Windows (GraphPad Software, San Diego,
California USA, www.graphpad.com). A P value less than 0.05 was considered significant.
4.4
4.4.1

Results
Profiling of planktonic and biofilm proteins
To identify the overexpressed biofilm formation proteins, two different growth bacterial

cells lysates were separated on 2-DE SDS-PAGE gel and overlayed to compare which protein
spots were overexpressed when pneumococcus forms a biofilm. The proteins that were only
overexpressed during biofilm growth were selected for mass spectrometry analysis. As shown in
Figure 4.1, 9 proteins were selected from biofilm growth for further analysis. These 9 proteins
were quantitated by ImageJ to confirm the overexpression (Table A.3) (SYBIL, 2022). Selected
9 proteins were identified by mass spectrometry analysis (Table A.4). From mass spectrometry
analysis, pneumococcal membrane proteins especially lipoproteins of ABC transporter were
selected for this study. Based on isoelectric point, molecular weight, peptide coverage and
probability score, protein spot #1 and #7 were identified as AmiA (SP_1891, WP_000742235.1)
and SP_0148 (WP_000724931.1) respectively (Table A.4).
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Figure 4.1

Profiling of planktonic and biofilm formation proteins on 2DE gels.

Each 50µg of proteins were separated on 2DE gels and stained with Coomassie blue.
Overexpressed biofilm proteins compared to planktonic proteins and proteins are only expressed
in biofilm formation proteins were selected. (A) planktonic proteins (B) biofilm formation
proteins.
4.4.2

Transcriptional level of biofilm formation proteins
Two lipoproteins (AmiA, SP_0148) were identified that they were overexpressed during

biofilm formation from 2DE SDS-PAGE gel. Additionally, we investigated their gene regulation
in transcriptional level by qPCR. We identified that when they form biofilm, both amiA and
SP0148 were upregulated (Figure 4.2). Compared to planktonic stage, amiA was upregulated
about 3.7-fold and SP0148 was upregulated about 3-fold during biofilm formation.

61

Figure 4.2

RNA transcriptional differences between planktonic and biofilm pneumococci.

Gene expression of amiA and SP0148 were assessed by qRT-PCR in planktonic (black) and
biofilm (gray). Fold changes were calculated by ΔΔCT analysis with housekeeping gene, gyrA,
as an internal control.
4.4.3

Biofilm assay and Growth curves
Our growth curves result showed that deletion of amiA and SP0148 did not affect growth

of pneumococcus. We identified that growth of 3 strains were not affected by regular media
(THY, C+Y). When they were grown in 50% TH medium, O.D. measurement of AmiA mutant
mid-log phase was slightly lower than other strains, but overall growth was not affected (Figure
B.3).
The unencapsulated TIGR4 derivative strain, T4R and its mutants: AmiA and SP_0148
were grown in 50% TH medium to form biofilm. Biofilm formation was quantified by crystal
violet staining method. As shown in Figure 4.3, AmiA and SP_0148 mutants decreased in
biofilm formation significantly.
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Figure 4.3

Effect of protein mutation on biofilm density

Biofilm density was measured by crystal violet staining. The stained biofilm was read in a
BioTek spectrophotometer at O.D.540nm. Data shown are the mean ±SD. Asterisk indicates the
statistical significance of student t-test at P < 0.05.
4.4.4

Adhesion assay and blocking assay
Since pneumococcus colonizes the human nasopharynx, Detroit 562 cells were incubated

with 3 different T4R strains to investigate their colonization. Deletion of AmiA did not affect
pneumococcal colonization. However, we found that SP_0148 mutant decreased their adherence
to Detroit 562 cells by half compared to wild type (Figure 4.4).
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To further confirm the role of AmiA and SP_0148 proteins in pneumococcal colonization
in nasopharynx, Detroit 562 cells were pre-blocked with recombinant AmiA or SP_0148 or both
proteins prior to incubation with T4R. When Detroit 562 cells were pre-blocked with both
recombinant proteins, there was decrease in binding of pneumococcus compared to other groups
but it was not significantly decreased. However, there was no significant difference between
control group and pre-blocked with only one protein groups (Figure 4.4).

Figure 4.4

Binding of T4R strains to human nasopharyngeal epithelial cells

(A) Detroit 562 cells were incubated with S. pneumoniae T4R wild type and mutants at MOI of 1
for 30 min. After washing, the numbers of S. pneumoniae T4R bound to Detroit 562 cells were
determined by plate counts. (B) Detroit 562 cells were pre-blocked with 200µg of recombinant
AmiA or SP_0148, or both proteins for 1 hr at 37℃ prior to incubation with T4R. After washing,
the numbers of S. pneumoniae T4R bound to Detroit 562 cells were determined by plate counts.
Experiments were performed three times in triplicate. Data shown are the mean ±SD. Asterisk
indicates the statistical significance of student t-test at P < 0.05.
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4.5

Discussion
Streptococcus pneumoniae cause bacterial pneumonia, meningitis, and otitis media in

young children and estimates of deaths are ~1 million worldwide (O'brien et al., 2009). However,
current licensed serotype based pneumococcal vaccines (PCV, PPSV) protect against only a
limited number of more than 100 serotypes. Undoubtedly, these vaccines have significantly
decreased mortality and cases of IPD. However, there are several limitations to the current
vaccines. They are relatively expensive, do not provide the protection against all serotypes of
pneumococcus and the prevalence of serotypes varies depending on geographical regions
(Ginsburg et al., 2012). The previous study indicated that among their study group, there was no
significant difference in colonization rate between vaccinated and unvaccinated group, and the
group of children most at risk for IPD had the highest colonization rate (Flamaing et al., 2010).
Current vaccines can protect against only of the specific serotypes that are included in
vaccines. Even though vaccines were introduced, some of the lesser immunogenic serotypes
included in the vaccines, such as serotypes 6, 14, 19, and 23, can still colonize humans and cause
most cases of IPD (Mehr & Wood, 2012). The previous study indicated that vaccination can shift
the majority of IPD causing serotypes. After vaccination, the overall cases of IPD decreased, but
other non-vaccine serotypes causing IPD has increased significantly among native Alaskan
children (Singleton et al., 2007). Therefore, we need to develop highly conserved protein-based,
serotype independent vaccines that can provide the protection against all type of pneumococcus.
However, there are still hurdles we need to overcome to develop effective protein-based
vaccines. First of all, protein vaccines have to elicit the strong CD4 T-cell and IL-17A immune
responses in order to provide better protection against pneumococcus (Ginsburg et al., 2012).
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Additionally, vaccines need to be cost effective and simple to manufacture which will facilitate
developing countries access to the vaccines.
Colonization is prerequisite for development of pneumococcal disease and transmission.
In human oral, streptococcal spp. including Streptococcus mutans, Streptococcus gordonii, and
Streptococcus intermedius biofilms form within the oral cavity (Cvitkovitch et al., 2003).
Likewise, S. pneumoniae forms biofilms during colonization of the nasopharynx. Biofilms can
provide protection from antibiotics and the host immune system. Pneumococcal biofilms showed
low level of virulence but increased genetic exchange and transformation rates (Chao et al.,
2015). Several studies have used in different methods to identify key proteins in biofilm
formation and characterize their roles in biofilm formation and colonization. A previous
transposon mutant screens identified that several mutants had insertions in genes including aliB,
cbpA, rlrA or rrgA showed higher biofilm density (Muñoz-Elías et al., 2008). Another study
identified that CbpA, LytA, and LuxS play an important role in biofilm formation from mutant
study. Thus, biofilm formation enhanced adherence to nasopharyngeal cells but led to a
reduction in invasion (Blanchette-Cain et al., 2013).
In this study, we identified broad proteomic differences in membrane protein expression
of planktonic and biofilm pneumococci. Two proteins, AmiA and SP_0148, were shown to
increase both RNA transcription and protein expression during biofilm formation. Additionally,
mutant strains formed less biofilm compared to wild type. Deletion of SP_0148 showed
decreased adherence to Detroit 562 cells compared to wild type and the AmiA mutant. No
significant difference in adhesion was seen when Detroit 562 cells were pre-blocked with
recombinant AmiA or SP_0148 protein, but incubation with both proteins could decrease
pneumococcal adherence slightly. These results can suggest that there would be major proteins
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are involved in colonization and interaction between multiple pneumococcal surface proteins can
enhance their colonization rate. The human nasopharynx is primary site of pneumococcal
colonization, and the nasopharyngeal environment is known to have poor nutrients and lower
temperature than normal body temperature. A previous study showed that harsh environment of
nasopharynx enhances genetic exchange of pneumococcus (Marks, Reddinger, et al., 2012). This
can contribute to multi-drug resistance in pneumococcus. We mimicked low temperature and
limited nutrient environment of the nasopharynx and identified biofilm formation proteins that
were overexpressed. Understanding of pneumococcal biofilm and their key proteins will aid
selection of protein-based vaccine candidates.
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CHAPTER V
CONCLUSIONS
Currently available pneumococcal vaccines, the pneumococcal conjugate vaccine (PCV)
and pneumococcal polysaccharide vaccine (PPSV), successfully prevent invasive pneumococcal
disease (IPD) caused by vaccine serotypes. However, there are limitations to these vaccines
including serotype dependence, geographical variation, and serotype replacement in
pneumococcal ecology. Even though vaccines are available, millions of children die of
pneumococcal disease worldwide every year (O'brien et al., 2009). Development of conserved
pneumococcal protein-based vaccines is needed to provide broad protection against all serotypes.
Additionally, protein-based vaccines should decrease the colonization levels below the disease
threshold, since colonization is prerequisite for IPD (Pichichero et al., 2016).
Selection of proteins for protein-based vaccines is important and these protein candidates
should ideally prevent both invasive disease and non-invasive pneumococcal colonization in
non-serotype dependent manner. There are numerous candidates for pneumococcal protein-based
vaccines, including histidine triad protein family, PhtD and PhtE, which are surface exposed
proteins and expressed by most pneumococcal strains. The choline binding surface protein,
PcpA, was also shown to elicit serum antibody response during pneumococcal lung infection and
colonization (Kaur et al., 2011). One of the most important virulence factors of pneumococcus,
pneumolysin, is also an attractive candidate for eliciting host immunity and detoxified
pneumolysin produces protective, pneumolysin-neutralizing antibodies (Salha et al., 2012).
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As a first step of this study, we have constructed a novel protein expression vector, pOS1,
described in Chapter II. This new system using Staphylococcus aureus (S. aureus) as an
expression host cell has advantages including production of secreted proteins which does not
require cell lysis and IPTG or other induction methods. Proteins produced by this system are
made in a Gram-positive background protein and contain no contaminating LPS. This new vector
system is ideal for Streptococcus pneumoniae surface proteins. We also determined the optimum
S. aureus culture medium for protein production by this system. This vector system was used to
successfully express various pneumococcal proteins that were used in this dissertation.
Additionally, we confirmed that the pOS1 vector could express a human protein, Annexin a2
(ANXA2), in S. aureus (data not shown). This new system will allow researchers to express high
concentrations of LPS-free proteins from various species for their research.
Proteins expressed from Chapter II were used in Chapter III to identify specific host
cellular receptors. We have chosen lipoprotein of manganese transporter, pneumococcal surface
adhesin A (PsaA) since this is one of the promising protein-based vaccine candidates and is
known to play an important role in colonization. A previous study identified that PsaA could
interact with E-cadherin which is involved in cell-cell junction (Anderton et al., 2007). We
utilized 2DE SDS-PAGE and far-western method to identify another cellular receptor of PsaA.
From far-western and mass spectrometry analysis, we identified that ANXA2 could interact with
PsaA.
To understand more about the ANXA2 and PsaA interaction, we utilized lentiviral
transfection and transduction method to express ANXA2 in human kidney epithelial cells (HEK
293 T/17) which express minimal of ANXA2 compared to other epithelial cell types. Adhesion
assays were conducted with ANXA2 transduced HEK 293 T/17 cells and non-transduced HEK
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293 T/17 cells to investigate the effect of ANXA2 in pneumococcal colonization. As we
expected, binding of pneumococcus to ANXA2 transduced cells was significantly higher than
non-transduced HEK 293 T/17 cells. Interestingly, we did not see any significant difference in
binding of a PsaA mutant strain with ANXA2 transduced cells and non-transduced cells. The
PsaA mutant strain actually had increased adherence to both transduced and non-transduced
HEK 293 T/17 cells compared to wildtype. This result can suggest that PsaA could mask other
pneumococcal adhesins as was shown for surface protein G (SasG) of S. aureus masking the
binding of S. aureus clumping factor B (ClfB) to cytokeratin of host cells (Corrigan et al., 2007).
Additionally, we have previously shown that loss of proteins involved in metal acquisition can
impact expression of numerous pneumococcal surface proteins including known and predicted
adhesins (Lindsey R Brown et al., 2016).
As a future plan, we will investigate the effect of ANXA2 in pneumococcal adherence to
other nasopharyngeal and lung epithelial cells when the anxA2 gene is deleted. We will utilize a
CRISPR-Cas9 gene editing method to delete ANXA2 from epithelial cells. Additionally, we will
investigate the ligand of ANXA2 and PsaA by expressing fragments of PsaA and conducting
binding studies. This will allow us to better understand which region of ANXA2 can interact
with PsaA and other pneumococcal surface proteins.
In Chapter IV, we investigated broad proteomic profiling of planktonic and biofilm
formation membrane proteins by 2DE SDS-PAGE gel analysis. Pneumococcal biofilm growth
provides pneumococcal resistance to antibiotics and the host immune response. During biofilm
formation in the human nasopharynx, pneumococcus is exposed to lower temperature (34℃)
than normal body temperature (37℃). Thus, some pneumococcal strains displayed reduced
biofilm mass when grown at 37℃ compared to 34℃ (Marks, Reddinger, et al., 2012).
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Additionally, this lower temperature (34℃) is known to be an optimal temperature for
transformation, allowing pneumococci to undergo genetic exchange from other organisms and
increasing the prevalence of multi-drug resistant strains (Reinert, 2009). Based on these findings,
we characterized proteins produced during the production of biofilm at 34℃.
We showed that 2 of ABC transporters: AmiA and SP_0148 were upregulated and
overexpressed during biofilm formation. Deletion of these two genes showed less biofilm
formation compared to wild type. We did not find significant differences in colonization between
wild type and AmiA mutant strain but, SP_0148 mutant showed decreased in adherence to
Detroit 562 cells.
We also have evidence that these two lipoproteins could interact with ANXA2 by farwestern blot (data not shown). This result suggests that ANXA2 could be a common receptor for
multiple pneumococcal surface proteins. Since various pneumococcal surface proteins are
involved in colonization of human nasopharyngeal cells, investigating which region of ANXA2
interacts with other pneumococcal surface proteins could allow us to develop a strategy for
blocking colonization by blocking ANXA2 binding.
The colonization of pneumococcus is prerequisite for transmission and invasive
pneumococcal disease. Bacteria utilize their surface exposed proteins to interact with host cells
for colonization. For this reason, understanding which pneumococcal surface proteins are
involved in colonization and identifying their host cellular receptors is an important study step in
the development of conserved proteins-based vaccines. In this dissertation, we constructed novel
protein expression vector to express some of the pneumococcal proteins for this study (Chapter
II). We identified ANXA2 as the host receptor for PsaA and demonstrated a role for ANXA2 in
colonization (Chapter III). Additionally, we mimicked the human nasopharyngeal environment
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and showed biofilm formation. From proteomic profiling of planktonic and biofilm surface
proteins, we showed which proteins are involved in biofilm formation and their role in
colonization (Chapter IV).
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Table A.1

Sequence of sequencing primer and amplicon size of each empty vector itself with
sequencing primer
Sequencing primer_F

5’-GCTAAATGATGCTCAAGCACC-3’

Sequencing primer_R

5’-CACACAGGAAACAGCTATGACC3’

pOS1-SEC-6x His vector
amplicon size

472bpa

pOS-Hlb-6x His vector
amplicon size

706bp

pOS-ETA-6x His vector
601bp
amplicon size
The amplicon size of each 3 different vectors correspond to when the vector itself (without gene
of interest insertion) is amplified with sequencing primer set. abp: Base pair
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Table A.2

Components of buffers for nickel chromatography
8x Charge buffer
8x Binding buffer

400mM NiSO4
160mM Tris-base
4M NaCl
40mM Imidazole
pH 7.9

8x Wash buffer

160mM Tris-base
4M NaCl
480mM Imidazole
pH 7.9

4x Elution buffer

80mM Tris-base
2M NaCl
4M Imidazole
pH 7.9

4x Stripping buffer

80mM Tris-base
0.4M EDTA
2M NaCl
pH 8.0

All the buffers were made either 4x or 8x concentrated in advance of purification and buffers
were diluted into 1x in water for nickel chromatography.
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Table A.3

Quantified planktonic and biofilm formation protein spots on 2DE SDS-PAGE gel
by ImageJ

Protein spot #
1
2
3
4
5
6
7
8
9

Planktonic
1060.497
1170.184
2039.681
1046.731
1497.468
959.225
237.314
110.256
99.142

Biofilm
1379.255
2158.217
2234.614
5084.690
1609.397
1291.740
1312.486
2054.324
1753.159
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Table A.4

Mass spectrometry analysis results of biofilm formation proteins

Protein spot #

Accession

Coverage

# of peptides

1

WP_000742235.1 50.08

28

Molecular
weight (kDa)
72.4

2

WP_000116479.1 65.34

31

47.2

3

WP_000724057.1 40.52

12

56.2

4

WP_001042809.1 21.76

6

54.7

5

WP_001096747.1 11.31

3

41.9

6

WP_000260666.1 15.22

4

35.8

7

WP_000724931.1 78.99

76

30.6

8

WP_000161399.1 50.18

12

30.6

9

WP_000932644.1 15.46

2

24.4

One protein was selected from each protein spot that has best coverage.
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Figure B.1

Purified proteins on SDS-PAGE gel were used in this study
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Figure B.2

CD spectra of proteins PsaA (blue), ANXA2 (red), the sum of both spectra
(purple) and the 1:1 mixture (green).

(A) The CD spectra of PsaA, ANXA2 (HEK) and the mixture after incubation for 1 hr at 25 °C.
(B) Similar to (A), but with ANXA2 (E. coli). (C) and (D) are similar to (A) and (B), but
incubation occurred for 1 hr at 37 °C. The similarity of the green and purple curves suggests that
the secondary structure is largely retained in the protein mixtures.
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Figure B.3

Growth curves of T4R strains in different media

Three different T4R strains (T4R, AmiA mutant, SP_0148 mutant) were inoculated in 3 different
media. They were grown at 34℃ for 48 hours and read at OD600 nm every 1hr.
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